<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6832525\results\search\disease\results.xml">
  <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Yellow fever" post="virus (YFV) represents a re-emerging zoonotic pathogen, transmitted by"/>
  <result pre="pathogen, transmitted by mosquito vectors to humans from primate reservoirs." exact="Sporadic" post="outbreaks of YFV occur in endemic tropical regions, causing"/>
  <result pre="outbreaks of YFV occur in endemic tropical regions, causing a" exact="viral" post="hemorrhagic fever (VHF) associated with high mortality rates. Despite"/>
  <result pre="antiviral treatments currently exist. Therefore, YFV represents a neglected tropical" exact="disease" post="and is chronically understudied, with many aspects of YFV"/>
  <result pre="review the current state of YFV research, focusing on the" exact="viral" post="lifecycle, host responses to infection, species tropism and the"/>
  <result pre="against this re-emerging pathogen which continues to cause devastating disease." exact="yellow fever" post="virus flavivirus entry factor global diversity yellow fever virus"/>
  <result pre="devastating disease. yellow fever virus flavivirus entry factor global diversity" exact="yellow fever" post="virus tropism animal models transmission and vector control vaccine"/>
  <result pre="vaccine host immune response E protein structure re-emerging virus 1." exact="General" post="Introduction Yellow fever was historically the first described viral"/>
  <result pre="immune response E protein structure re-emerging virus 1. General Introduction" exact="Yellow fever" post="was historically the first described viral hemorrhagic fever (VHF)"/>
  <result pre="1. General Introduction Yellow fever was historically the first described" exact="viral" post="hemorrhagic fever (VHF) and its causative agent, the yellow"/>
  <result pre="described viral hemorrhagic fever (VHF) and its causative agent, the" exact="yellow fever" post="virus (YFV), is the prototypic member of the family"/>
  <result pre="reside in Africa [6]. YFV represents a zoonotic pathogen and" exact="complete" post="eradication in tropical regions is not achievable due to"/>
  <result pre="group of small enveloped viruses representing over 100 species [10]." exact="Viral" post="genomes from Flaviviridae members are non-segmented positive-stranded RNAs ranging"/>
  <result pre="and [10]). Members of the Flaviviridae which cause a significant" exact="disease" post="burden in humans are highlighted on the tree presented"/>
  <result pre="contains a number of important human pathogens which can cause" exact="acute" post="infections, including dengue virus (DENV), West Nile virus (WNV),"/>
  <result pre="acute infections, including dengue virus (DENV), West Nile virus (WNV)," exact="Japanese encephalitis" post="virus (JEV) and Zika virus (ZIKV) (Figure 1). Transmission"/>
  <result pre="infections, including dengue virus (DENV), West Nile virus (WNV), Japanese" exact="encephalitis" post="virus (JEV) and Zika virus (ZIKV) (Figure 1). Transmission"/>
  <result pre="(ZIKV) (Figure 1). Transmission is mediated via mosquito vectors and" exact="infection" post="of humans can cause a range of clinical outcomes,"/>
  <result pre="cause a range of clinical outcomes, ranging from asymptomatic to" exact="encephalitis" post="(WNV, JEV and ZIKV) or fatal hemorrhagic fever (YFV"/>
  <result pre="imports into non-endemic regions [15,17]. This is compounded by a" exact="limited" post="vaccine production, which can easily be overwhelmed by a"/>
  <result pre="easily be overwhelmed by a large YFV outbreak, and the" exact="collapse" post="of vector control programs [1,14,15], coupled with large populations"/>
  <result pre="of reverse genetic systems [19,20,21,22,23,24], YFV remains a neglected tropical" exact="disease" post="attracting relatively little research attention [25]. This is, in"/>
  <result pre="in infected humans. 2. Clinical Outcomes and Potential Therapeutic Options" exact="Infection" post="with YFV has a broad spectrum of clinical manifestations"/>
  <result pre="associated with high mortality rates. Indeed, estimates indicate only one" exact="symptomatic" post="case for every 7â€&quot;12 cases that remain clinically silent"/>
  <result pre="cases that remain clinically silent [5]. In the majority of" exact="symptomatic" post="cases, YFV infection is a self-limiting disease with abrupt"/>
  <result pre="clinically silent [5]. In the majority of symptomatic cases, YFV" exact="infection" post="is a self-limiting disease with abrupt onset of fever"/>
  <result pre="the majority of symptomatic cases, YFV infection is a self-limiting" exact="disease" post="with abrupt onset of fever and pain (predominantly myalgia,"/>
  <result pre="an incubation period of 3â€&quot;6 days. In this phase, YFV" exact="infection" post="is difficult to diagnose, as symptoms are unspecific. The"/>
  <result pre="abnormalities during this â€œperiod of infectionâ€� include elevated liver enzymes," exact="leukopenia" post="and proteinuria. A phase of improvement, lasting up to"/>
  <result pre="during this â€œperiod of infectionâ€� include elevated liver enzymes, leukopenia" exact="and proteinuria." post="A phase of improvement, lasting up to two days,"/>
  <result pre="occur in all cases. In around 15% of patients, the" exact="disease" post="progresses to a â€œtoxic phaseâ€�, which is characterized by"/>
  <result pre="by the return of fever, nausea, vomiting, epigastric pain and" exact="renal insufficiency" post="[18]. This is characterized by systemic viscerotropic disease and"/>
  <result pre="epigastric pain and renal insufficiency [18]. This is characterized by" exact="systemic" post="viscerotropic disease and liver injury is a hallmark of"/>
  <result pre="and renal insufficiency [18]. This is characterized by systemic viscerotropic" exact="disease" post="and liver injury is a hallmark of this phase"/>
  <result pre="of this phase [29], leading to jaundice and contributing to" exact="bleeding" post="diathesis, which may lead to more severe hemorrhaging. It"/>
  <result pre="as DENV, is believed to reduce the severity of YFV" exact="infections" post="[5,32]. Patients who survive the disease may suffer from"/>
  <result pre="the severity of YFV infections [5,32]. Patients who survive the" exact="disease" post="may suffer from fatigue and may have elevated liver"/>
  <result pre="by YFV and the large populations in tropical Africa and" exact="Central" post="and South America at risk of potentially catastrophic epidemics,"/>
  <result pre="potentially catastrophic epidemics, today, treatment options for infected individuals are" exact="limited" post="to relief of symptoms and intensive care support of"/>
  <result pre="disease. Presently, no specific licensed treatment options for YFV-associated severe" exact="disease" post="are available. As development of new drugs is expensive"/>
  <result pre="targeted at other members of the family Flaviviridae, most prominently" exact="hepatitis C" post="virus (HCV) and DENV. Ribavirin, a nucleoside analog, in"/>
  <result pre="use against HCV, is a nucleotide analog inhibitor of the" exact="viral" post="RdRp NS5B. It also has described antiviral activity against"/>
  <result pre="but approaches targeting the hostâ€™s immune response in severe YFV" exact="disease" post="are lacking. When patients present with severe symptoms, the"/>
  <result pre="members of the Flaviviridae. These include (a) attachment of the" exact="viral" post="particle to target cells, (b) interaction with surface receptors"/>
  <result pre="(b) interaction with surface receptors for internalization, (c) fusion of" exact="viral" post="and endosomal membranes and release of the nucleocapsid into"/>
  <result pre="disintegration of the nucleocapsid, (e) translation and replication of the" exact="viral" post="genome, (f) assembly and maturation of viral particles and"/>
  <result pre="replication of the viral genome, (f) assembly and maturation of" exact="viral" post="particles and (g) release of nascent virions [45]. Currently,"/>
  <result pre="humans requires further investigation. 3.1. YFV Virion Composition and E" exact="Protein" post="Functions The YFV virion is spherical in shape, with"/>
  <result pre="of three domains: DI, DII and DIII (see Figure 2A," exact="upper" post="panel). In the pre-fusion state, the E protein forms"/>
  <result pre="virionâ€™s lipid envelope in the pre-fusion state (See Figure 2A," exact="lower" post="panel). DIII harbors epitopes essential for neutralization of YFV"/>
  <result pre="binding the E protein trimers in their post-fusion state [54]." exact="Structural" post="and functional studies have suggested conformational change from a"/>
  <result pre="located at the apex of the trimer (see Figure 2B," exact="lower" post="panels). To date, only the structure of the immature"/>
  <result pre="DIII is suspected to mediate interaction with cellular receptors during" exact="infection" post="[45]. While flavivirus entry into target cells is incompletely"/>
  <result pre="GRK2 was reported to both promote YFV entry and enhance" exact="viral" post="RNA synthesis, properties which were conserved across key members"/>
  <result pre="to mediate DENV infection, with TIM-1 and TIM-4 also enhancing" exact="infection" post="rates for WNV and YFV-17D to differing degrees, while"/>
  <result pre="infection rates for WNV and YFV-17D to differing degrees, while" exact="herpes" post="simplex virus-1 (HSV-1) infection rates were unaffected [67]. Therefore,"/>
  <result pre="and YFV-17D to differing degrees, while herpes simplex virus-1 (HSV-1)" exact="infection" post="rates were unaffected [67]. Therefore, these cellular factors represent"/>
  <result pre="also facilitates attachment for the related flaviviruses DENV [68] and" exact="tick-borne encephalitis" post="virus (TBEV) [69], as well as unrelated viruses, including"/>
  <result pre="facilitates attachment for the related flaviviruses DENV [68] and tick-borne" exact="encephalitis" post="virus (TBEV) [69], as well as unrelated viruses, including"/>
  <result pre="[69], as well as unrelated viruses, including HSV and human" exact="immunodeficiency" post="virus (HIV) [70,71]. Indeed, the antiviral effect of PI-88,"/>
  <result pre="whether a ubiquitous cellular receptor is responsible for facilitating flavivirus" exact="infection" post="of permissive cells [73]. Similarly to DENV, YFV is"/>
  <result pre="has revealed many potential host factors influencing WNV or DENV" exact="infection" post="of human or drosophila cell-lines [65,75]. Analogous to mammalian"/>
  <result pre="can be pin-pointed to eleven mutations within the E proteinâ€™s" exact="primary" post="amino acid sequence (see Figure 2), which occurred during"/>
  <result pre="increased heparin sulfate affinity is known to be important for" exact="viral" post="spread and attenuation [68,78]. In summary, mechanistic insights into"/>
  <result pre="and attenuation [68,78]. In summary, mechanistic insights into the YFV" exact="infection" post="process, in addition to many host factors implicated in"/>
  <result pre="targeting the HCV entry factor CLDN1 via a mAb inhibited" exact="viral" post="entry and promoted viral clearance in a humanized mouse"/>
  <result pre="factor CLDN1 via a mAb inhibited viral entry and promoted" exact="viral" post="clearance in a humanized mouse model [81]. 3.3. Polyprotein"/>
  <result pre="Processing, RNA Replication and Virion Maturation After entry and uncoating," exact="viral" post="RNA is transported to the endoplasmic reticulum (ER) and"/>
  <result pre="modified by cellular glycosyltransferases, and the liberation of ten mature" exact="viral" post="proteins is mediated by both host and viral proteases"/>
  <result pre="ten mature viral proteins is mediated by both host and" exact="viral" post="proteases [83,84]. The processed polyprotein produces three structural proteins"/>
  <result pre="NS3, NS4A, NS4B, and NS5) [85] which are involved in" exact="viral" post="RNA replication on ER membranes (Figure 3 and Table"/>
  <result pre="although they differ in critical aspects: they possess a methylated" exact="type 1" post="cap structure at the 5â€²-terminus (me7-GpppA-me2) and lack a"/>
  <result pre="(me7-GpppA-me2) and lack a polyadenylation signal at the 3â€²-terminus. The" exact="type 1" post="cap is synthesized by virally encoded proteins: an NS3-encoded"/>
  <result pre="NS3 also possesses a C-terminally encoded NTPase/RNA helicase to remove" exact="viral" post="RNA secondary structures and double-strand RNA (dsRNA) intermediates, generated"/>
  <result pre="possesses a C-terminally encoded NTPase/RNA helicase to remove viral RNA" exact="secondary" post="structures and double-strand RNA (dsRNA) intermediates, generated by NS5"/>
  <result pre="during virus replication [96]. The flavivirus NS5 protein encodes the" exact="viral" post="RdRp, synthesizing negative-stranded RNA, which forms a double-stranded complex"/>
  <result pre="capping process via inhibition of the methyltransferase activity and inhibited" exact="viral" post="replication [99]. NS1, NS2A, NS4A and NS4B represent hydrophobic"/>
  <result pre="replication and assembly processes [108], facilitating association of newly synthesized" exact="viral" post="RNA with structural proteins to produce immature virions during"/>
  <result pre="proteins to produce immature virions during virion assembly [109,110]. The" exact="viral" post="lipid-envelope is acquired from the host cell by budding"/>
  <result pre="immature virions during virion assembly [109,110]. The viral lipid-envelope is" exact="acquired" post="from the host cell by budding from the lumen"/>
  <result pre="protein produces a rearrangement of the E protein [112], generating" exact="infectious" post="virions that are fusogenic under low pH conditions [27]."/>
  <result pre="infectious virions that are fusogenic under low pH conditions [27]." exact="Viral" post="replication, assembly, and maturation, as well as host factors"/>
  <result pre="assembly, and maturation, as well as host factors essential for" exact="viral" post="propagation, are potential targets for the development of anti-YFV"/>
  <result pre="of anti-YFV drugs. However, a better understanding of determinants of" exact="viral" post="replication and the virus-host interactome are required for YFV:"/>
  <result pre="confirmation with YFV is lacking. 4. Host Responses to YFV" exact="Infection" post="4.1. Cytokine Induction by YFV Using paraffin-embedded liver tissue"/>
  <result pre="it was demonstrated that CD4+ T cells represent the main" exact="infiltrating" post="cell population into liver tissue, with a high proportion"/>
  <result pre="infected hepatocytes, indicating that apoptosis, rather than necrosis, is the" exact="primary" post="cell-death mechanism in YFV-infected livers [113]. With respect to"/>
  <result pre="and anti-inflammatory cytokines is associated with the immunopathology of YFV" exact="infection" post="and responses to YFV-17D vaccination. 4.2. Cellular Responses to"/>
  <result pre="YFV NS5 interacts with STAT2 when STAT1 is phosphorylated during" exact="type I" post="IFN signaling: the E3 ubiquitin ligase TRIM23 polyubiquinates NS5,"/>
  <result pre="and macrophages (MDM) were also shown to be susceptible to" exact="infection" post="with YFV wild-type Asibi and 17D vaccine strains, with"/>
  <result pre="and 17D vaccine strains, with differences in cytokine responses to" exact="infection" post="observed between strains. Additionally, only MoDCs infected with YFV-17D"/>
  <result pre="be the highest producers of IFN-Î³, which protects against viscerotropic" exact="disease" post="in YFV-17D infection but not for wild-type virus, indicating"/>
  <result pre="producers of IFN-Î³, which protects against viscerotropic disease in YFV-17D" exact="infection" post="but not for wild-type virus, indicating that YFV vaccine"/>
  <result pre="CD69 increases, concomitant with increased circulating IFN-Î³ [123] and 17D-YFV" exact="infection" post="stimulated vigorous early NK cell responses in vivo primed"/>
  <result pre="stimulated vigorous early NK cell responses in vivo primed by" exact="type I" post="and III IFNs [124]. 4.3. Pattern Recognition Receptors and"/>
  <result pre="(RLR) family, are critical for initiating the IFN response to" exact="infection" post="via recognition of intracellular viral RNA [125]. While RIG-I"/>
  <result pre="initiating the IFN response to infection via recognition of intracellular" exact="viral" post="RNA [125]. While RIG-I recognizes dsRNA, which possesses a"/>
  <result pre="Both RIG-1 and MDA5 have important roles in restricting flavivirus" exact="infections" post="([127] as reported for DENV [128], WNV [129] and"/>
  <result pre="MAVS and STING to mediate their antiviral effects [131]. However," exact="viral" post="genome modifications can prevent RIG-I recognition, with cap1 2â€²O-methylation"/>
  <result pre="flaviviruses: cGAS knockout mice were more susceptible to lethal WNV" exact="infection" post="outcomes when compared to wild-type mice [134], and DENV"/>
  <result pre="the engagement of inflammasomes and signalosomes after the detection of" exact="viral" post="danger signals. This occurs via activation of caspase-1, which"/>
  <result pre="While inflammasome activation has been reported for WNV and DENV" exact="infection" post="[126], the exact danger signals detected and its significance"/>
  <result pre="the exact danger signals detected and its significance in YFV" exact="infection" post="remains unclear. Together these studies implicate RLRs and the"/>
  <result pre="both pro- and anti-YFV effector genes are modulated by the" exact="type I" post="IFN response. In addition, some genes have panflaviviral potency,"/>
  <result pre="contribution of patient and tissue-specific differences in ISG expression to" exact="viral" post="clearance and the correlation between ISG induction and differential"/>
  <result pre="viral clearance and the correlation between ISG induction and differential" exact="disease" post="outcomes is currently unclear. 5. Tropism of YFV In"/>
  <result pre="broad patterns of tissue tropism and is disseminated systemically via" exact="infection" post="of multiple white cell subsets. With respect to organ"/>
  <result pre="subsets. With respect to organ tropism, the liver is the" exact="primary" post="target, although the heart, kidneys, liver, spleen, and less"/>
  <result pre="although the heart, kidneys, liver, spleen, and less frequently, the" exact="brain" post="tissue, can support YFV replication [18]. The natural host"/>
  <result pre="elicitation of antibody responses against YFV indicates a potentially productive" exact="infection" post="within these species, indicating that diverse mammalian species could"/>
  <result pre="species could represent YFV potential reservoirs [143] (see Section 8.3)." exact="Mouse" post="Models for YFV YFV research is currently limited as"/>
  <result pre="Section 8.3). Mouse Models for YFV YFV research is currently" exact="limited" post="as it remains challenging and expensive to establish workflows"/>
  <result pre="to establish workflows with non-human primates. While YFV has a" exact="limited" post="host species-tropism, artificial infection of laboratory mice and hamsters"/>
  <result pre="non-human primates. While YFV has a limited host species-tropism, artificial" exact="infection" post="of laboratory mice and hamsters is possible, although the"/>
  <result pre="laboratory mice and hamsters is possible, although the course of" exact="disease" post="differs from that observed in humans [144]. Nevertheless, a"/>
  <result pre="genetically modified or humanized mice have yielded insights into YFV" exact="infection" post="and dissemination in vivo. Single cell-tracking of YFV-17D dissemination"/>
  <result pre="in different mouse models identified novel YFV replication reservoirs in" exact="secondary" post="lymphoid compartments, with hematopoietic STAT1 knockout increasing virus-induced pathogenicity"/>
  <result pre="hepatocytes [145,146], and these animals represent ideal tools for monitoring" exact="systemic" post="YFV infection in vivo as both compartments are permissive"/>
  <result pre="and these animals represent ideal tools for monitoring systemic YFV" exact="infection" post="in vivo as both compartments are permissive for YFV."/>
  <result pre="neurotropic in rodents, primates and humans [147,148]. In contrast to" exact="polio" post="virus and reovirus, which infect the brain via the"/>
  <result pre="In contrast to polio virus and reovirus, which infect the" exact="brain" post="via the CNS, YFV-17D infects brain tissue by crossing"/>
  <result pre="reovirus, which infect the brain via the CNS, YFV-17D infects" exact="brain" post="tissue by crossing the blood-brain barrier [149]. A mouse-neurovirulent"/>
  <result pre="via the CNS, YFV-17D infects brain tissue by crossing the" exact="blood-brain barrier" post="[149]. A mouse-neurovirulent strain (SPYF) based on the Porterfield"/>
  <result pre="while patterns of YFV-17D dissemination in immunocompetent mice were restricted," exact="infection" post="of IFNAR knockout mice resulted in broad dissemination preceding"/>
  <result pre="infection of IFNAR knockout mice resulted in broad dissemination preceding" exact="viral" post="clearance, indicating that no barriers to dissemination exist in"/>
  <result pre="clearance, indicating that no barriers to dissemination exist in the" exact="absence of" post="type I IFN [152]. Furthermore, while I and II"/>
  <result pre="that no barriers to dissemination exist in the absence of" exact="type I" post="IFN [152]. Furthermore, while I and II type IFNs"/>
  <result pre="and II type IFNs contribute to control of YFV-17D infection," exact="type III" post="IFN was demonstrated to have immunomodulatory functions and was"/>
  <result pre="was protective against YFV-17D neuroinvasion in mouse models [153]. YFD-17D" exact="infection" post="of IFN-Î±/Î² receptor and STAT1 signaling molecule deficient mice"/>
  <result pre="IFN-Î±/Î² receptor and STAT1 signaling molecule deficient mice resulted in" exact="systemic" post="viscerotropic infection: a course of disease which resembles that"/>
  <result pre="deficient mice resulted in systemic viscerotropic infection: a course of" exact="disease" post="which resembles that observed in humans rather than the"/>
  <result pre="resembles that observed in humans rather than the typical encephalitic" exact="disease" post="course commonly reported for mice [154]. Finally, while many"/>
  <result pre="the common ability to antagonize IFN signaling and therefore enhance" exact="viral" post="replication, the YFV NS5 is unable to bind murine"/>
  <result pre="YFV replication in murine cells, which was correlated with an" exact="absence of" post="IFN-Î±/Î²-mediated NS5 ubiquitination [155]. Together, these mouse studies enhance"/>
  <result pre="for the development of the next generation of small animal" exact="disease" post="models for YFV, which should endeavor to recapitulate the"/>
  <result pre="disease models for YFV, which should endeavor to recapitulate the" exact="disease" post="course seen in humans. Thus, the generation of an"/>
  <result pre="has achieved eradication of smallpox, lowered the global incidence of" exact="polio" post="by 99% and reduced illness, disability and death from"/>
  <result pre="YFV was isolated from a Ghanaian patient suffering from mild" exact="yellow fever" post="and inoculated into rhesus macaques by direct blood/serum transfer"/>
  <result pre="Africa, virtually eradicating the disease. However, serial passaging in mouse" exact="brain" post="increased FNVâ€™s neurotropism, leading to high levels of post-vaccinal"/>
  <result pre="mouse brain increased FNVâ€™s neurotropism, leading to high levels of" exact="post-vaccinal encephalitis" post="in children. Consequently, the use of FNV was discontinued"/>
  <result pre="brain increased FNVâ€™s neurotropism, leading to high levels of post-vaccinal" exact="encephalitis" post="in children. Consequently, the use of FNV was discontinued"/>
  <result pre="between the three strains outlined above [160]. The Centre for" exact="Disease" post="Control and Prevention (CDC) recommends YF vaccination for travelers"/>
  <result pre="be exposed through needle stick injury or inhalation of aerosolized" exact="viral" post="droplets [161]. The YFV vaccine is a freeze-dried live-attenuated"/>
  <result pre="an antigen delivery platform for other experimental vaccines including HIV-1," exact="Lassa fever," post="malaria and DENV [175,176,177,178,179,180]. After early successes in outbreak"/>
  <result pre="delivery platform for other experimental vaccines including HIV-1, Lassa fever," exact="malaria" post="and DENV [175,176,177,178,179,180]. After early successes in outbreak prevention"/>
  <result pre="vaccine supply [182,183,184]. Furthermore, an unusually large outbreak of the" exact="disease" post="in Brazil in early 2017, including areas that previously"/>
  <result pre="previous strategies [185]. In order to maximize the impact of" exact="limited" post="vaccine supplies in a context of depleted global stockpiles,"/>
  <result pre="of 17DD [183,186]. 6.4. Limitations: Production and Adverse Reactions The" exact="disease" post="has re-emerged as a public health threat in recent"/>
  <result pre="in issues with supply and demand during outbreaks due to" exact="limited" post="production capabilities [187]. Another limiting issue during current production"/>
  <result pre="elicit protective host responses to these complex bio-therapeutics. Therefore, more" exact="stable" post="vaccines with reduced dependency on the cold chain represent"/>
  <result pre="stabilized by the addition of pirodavir and deuterium oxide, with" exact="viral" post="RNA and viral capsid resisting a 10-h incubation at"/>
  <result pre="addition of pirodavir and deuterium oxide, with viral RNA and" exact="viral" post="capsid resisting a 10-h incubation at 42 Â°C [190]."/>
  <result pre="during an epidemic, pregnant women, lactating women, people with severe" exact="immunodeficiency" post="due to symptomatic HIV or the presence of thymus"/>
  <result pre="pregnant women, lactating women, people with severe immunodeficiency due to" exact="symptomatic" post="HIV or the presence of thymus disorder, and hypersensitivity"/>
  <result pre="to symptomatic HIV or the presence of thymus disorder, and" exact="hypersensitivity" post="to chicken eggs [161,187]. In addition, there are common"/>
  <result pre="there are common side effects of the vaccine, ranging from" exact="muscle" post="aches, chills, flu-like symptoms, joint pain, mild fever, mild"/>
  <result pre="aches, chills, flu-like symptoms, joint pain, mild fever, mild rash," exact="muscle" post="weakness and swelling at the injection site. Using transcriptomic"/>
  <result pre="profiling of 17D-204 vaccinees, it has recently been demonstrated that" exact="symptomatic" post="outcomes to vaccination were associated with baseline endoplasmic reticulum"/>
  <result pre="[191]. The use of a live attenuated vaccine can prevent" exact="yellow fever," post="but vaccine-associated neurologic disease has been reported and is"/>
  <result pre="a live attenuated vaccine can prevent yellow fever, but vaccine-associated" exact="neurologic disease" post="has been reported and is a safety concern [192,193,194]."/>
  <result pre="live attenuated vaccine can prevent yellow fever, but vaccine-associated neurologic" exact="disease" post="has been reported and is a safety concern [192,193,194]."/>
  <result pre="memory loss, problems with breathing, behavioral changes, seizures, viscerotropic disease," exact="encephalitis" post="and death can occur. In addition, the vaccine is"/>
  <result pre="epidemic in Asia remains daunting and YFV is the only" exact="infectious disease" post="where an international vaccination certificate is required [160]. However,"/>
  <result pre="in Asia remains daunting and YFV is the only infectious" exact="disease" post="where an international vaccination certificate is required [160]. However,"/>
  <result pre="has been evidence of fake/forged certificates [198]. 6.5. Future Directions" exact="Yellow fever" post="is a re-emerging infectious disease, as vector control and"/>
  <result pre="certificates [198]. 6.5. Future Directions Yellow fever is a re-emerging" exact="infectious disease," post="as vector control and routine immunization strategies have dwindled"/>
  <result pre="this, the WHO has initiated a global strategy to eliminate" exact="yellow fever" post="epidemics (EYE) by 2026, focusing on management of global"/>
  <result pre="reduce adverse reactions, alternative vaccination approaches should be explored, including" exact="vaccinia" post="vector-based systems, DNA vaccines, inactivated 17D vaccines and recombinant"/>
  <result pre="with its basic principal to introduce synonymous mutations into the" exact="viral" post="genome [215] that would impose the least detrimental effects"/>
  <result pre="genome [215] that would impose the least detrimental effects on" exact="viral" post="fitness [216]. This approach has been applied to other"/>
  <result pre="This approach has been applied to other RNA viruses, including" exact="chikungunya" post="(CHIKV) and TBEV [217,218]. In summary, in addition to"/>
  <result pre="[199]. Hence, novel manufacturing techniques to produce large quantities of" exact="yellow fever" post="vaccine at short notice are required which also eliminate"/>
  <result pre="techniques to produce large quantities of yellow fever vaccine at" exact="short" post="notice are required which also eliminate the chicken embryo"/>
  <result pre="not well defined. This is due, in part, to the" exact="limited" post="animal models available to evaluate vaccine-induced immune responses [168]"/>
  <result pre="(Figure 4a). Collapsed clades contain closely related isolates from recent" exact="Brazilian" post="and Angolan outbreaks, in addition to 17D vaccine strains."/>
  <result pre="YFV sequences can be divided into six well-supported lineages: West" exact="African" post="lineages I and II (WAL I and WAL II),"/>
  <result pre="lineages I and II (WAL I and WAL II), South" exact="American" post="lineages I and II (SAL I and SAL II),"/>
  <result pre="I and II (SAL I and SAL II), the East" exact="African" post="lineage (EAL) and the Angola lineage (AL). In agreement"/>
  <result pre="lineage (AL). In agreement with a previous phylogenetic analysis of" exact="partial" post="[219] and full-length ORFs [16,27], our expanded analysis illustrates"/>
  <result pre="and full-length ORFs [16,27], our expanded analysis illustrates that South" exact="American" post="lineages are monophyletic, sharing a common ancestor with the"/>
  <result pre="lineages are monophyletic, sharing a common ancestor with the West" exact="African" post="lineages, and confirms a deep-divergence between these lineages and"/>
  <result pre="deep-divergence between these lineages and the more distantly related East" exact="African" post="and Angolan strains, indicating an ancient separation. This observation"/>
  <result pre="indicating an ancient separation. This observation is consistent with an" exact="African" post="origin for YFV, with South American lineages representing historical"/>
  <result pre="is consistent with an African origin for YFV, with South" exact="American" post="lineages representing historical import of West African YFV strains"/>
  <result pre="YFV, with South American lineages representing historical import of West" exact="African" post="YFV strains linked to European colonial expansions and the"/>
  <result pre="majority of studies utilize the YFV-17D vaccine strain which has" exact="atypical" post="properties [78], or its wild-type progenitor, the Asibi strain,"/>
  <result pre="studies should address this discrepancy: it is currently unknown whether" exact="infection" post="with isolates from different YFV lineages contributes to differential"/>
  <result pre="likely a reflection of the selective constraints imposed by the" exact="viral" post="transmission cycle: YFV experiences sequential bottlenecks upon continued cycling"/>
  <result pre="helicase domain of NS3, integral for RNA duplex unwinding during" exact="viral" post="replication, has a conserved function in the Flaviviridae and"/>
  <result pre="the outstanding YFV proteins will expand the number of potential" exact="viral" post="targets for future structure-based antiviral drug design studies. 8."/>
  <result pre="of NGS The use of NGS technologies allows recovery of" exact="complete" post="viral genomic sequences directly from infected patientsâ€™ material, and"/>
  <result pre="NGS The use of NGS technologies allows recovery of complete" exact="viral" post="genomic sequences directly from infected patientsâ€™ material, and these"/>
  <result pre="from infected patientsâ€™ material, and these metagenomic approaches have revolutionized" exact="infectious disease" post="outbreak diagnostics and surveillance in recent years [225]. In"/>
  <result pre="infected patientsâ€™ material, and these metagenomic approaches have revolutionized infectious" exact="disease" post="outbreak diagnostics and surveillance in recent years [225]. In"/>
  <result pre="initial diagnosis. These include Ebola viruses (EBOV), Marburg virus (MARV)," exact="Rift Valley fever" post="virus (RVFV), Junin virus (JUNV) and Crimean-Congo hemorrhagic fever"/>
  <result pre="(MARV), Rift Valley fever virus (RVFV), Junin virus (JUNV) and" exact="Crimean-Congo hemorrhagic fever" post="(CCHFV). The diagnostic capacity of NGS to discriminate between"/>
  <result pre="sequencing devices (MinION, Oxford Nanopore) have been deployed to monitor" exact="viral" post="outbreaks, including the West African 2013-16 EBOV outbreak [228]"/>
  <result pre="have been deployed to monitor viral outbreaks, including the West" exact="African" post="2013-16 EBOV outbreak [228] and the Lassa fever virus"/>
  <result pre="including the West African 2013-16 EBOV outbreak [228] and the" exact="Lassa fever" post="virus (LASV) outbreak in Nigeria in 2018 [229]. This"/>
  <result pre="the 2016â€&quot;2017 YFV outbreak in Brazil, generating data spatially correlating" exact="infections" post="of humans with infection of non-human primates [16]. These"/>
  <result pre="in Brazil, generating data spatially correlating infections of humans with" exact="infection" post="of non-human primates [16]. These data indicate that vector-mediated"/>
  <result pre="primates [16]. These data indicate that vector-mediated transmission in the" exact="Brazilian" post="outbreak was dominated by continued primate-to-human transmission rather than"/>
  <result pre="transmission rather than a human-to-human transfer often observed in explosive" exact="African" post="outbreaks. While future outbreaks are inevitable, rapid identification of"/>
  <result pre="vaccination programs and vector eradication campaigns. Additionally, in future outbreaks," exact="viral" post="sampling could be coupled with serological markers of infection"/>
  <result pre="outbreaks, viral sampling could be coupled with serological markers of" exact="infection" post="(anti-YFV antibodies) and patient DNA bio-banking to enable stratification"/>
  <result pre="DNA bio-banking to enable stratification of host-genetic correlates of YFV" exact="infection" post="outcomes, and correlation with host single nucleotide polymorphisms (SNPs)."/>
  <result pre="patient cohorts can facilitate advances in our understanding of within-host" exact="viral" post="evolution. Despite near-perfect environmental conditions, including the presence of"/>
  <result pre="infecting strains were closely related to each other and possessed" exact="limited" post="divergence from the Angola 1971 strain (three amino acid"/>
  <result pre="[12,233]. The action of strong purifying selection was detected throughout" exact="viral" post="genomes, with intra-host variation dominated by synonymous substitutions [233]."/>
  <result pre="the evolutionary rate of YFV has been shown to be" exact="lower" post="than that of DENV [234] and the YFV RdRp"/>
  <result pre="and dissemination in both mammals and arthropods, coupled with a" exact="limited" post="duration of infection in human hosts. 8.3. Identification of"/>
  <result pre="both mammals and arthropods, coupled with a limited duration of" exact="infection" post="in human hosts. 8.3. Identification of Novel Animal Reservoirs"/>
  <result pre="many zoonotic viruses cause severe pathology in humans, tolerance and" exact="absence of" post="disease is often observed in reservoir species [235]. After"/>
  <result pre="viruses cause severe pathology in humans, tolerance and absence of" exact="disease" post="is often observed in reservoir species [235]. After long"/>
  <result pre="suggested that primate density is often not sufficient to maintain" exact="stable" post="sylvatic transmission, and YFV reservoirs in non-primate species could"/>
  <result pre="and Haemogogus and Sabethes species in South America; 2. The" exact="intermediate" post="or savannah cycleâ€&quot;occurs in isolated rural communities on the"/>
  <result pre="of the epidemic [13]. Contrastingly, detailed analyses of the 2016â€&quot;2017" exact="Brazilian" post="YFV outbreak suggests the sylvatic cycle represents the dominant"/>
  <result pre="possible in geographic regions where competent vector species reside: the" exact="disease" post="is not contagious in their absence. This facet of"/>
  <result pre="is not contagious in their absence. This facet of the" exact="viral" post="life cycle has been exploited in the past to"/>
  <result pre="been controlled in Africa, vector control programs coupled with the" exact="absence of" post="a sylvatic cycle enabled its complete eradication from Europe"/>
  <result pre="coupled with the absence of a sylvatic cycle enabled its" exact="complete" post="eradication from Europe and North America, where devastating outbreaks"/>
  <result pre="wPip infected mosquitos of both sexes were less susceptible to" exact="infection" post="with the pathogenic flaviviruses DENV and ZIKV [246]. Pupal"/>
  <result pre="often replicate in mosquito mid-gut and targeting this site of" exact="viral" post="replication via genetic modification represents another possible strategy for"/>
  <result pre="expressed Loquacious and r2d2 to restore efficient siRNA suppression of" exact="viral" post="replication in the mosquito midgut [247]. Furthermore, attenuated YFV-17D"/>
  <result pre="profiles for distinct Ae. aegypti tissues, from both male and" exact="female" post="mosquitos at different stages of the reproductive cycle are"/>
  <result pre="research is imperative to expand current knowledge of the complex" exact="viral" post="life cycle and stimulate the development of novel anti-YFV"/>
  <result pre="of Yellow FeverYale J. Biol. Med.1982551791856758368 8.TheilerM.SmithH.H.The Use of Yellow" exact="Fever" post="Virus Modified by in Vitro Cultivation For Human ImmunizationJ."/>
  <result pre="in Vitro Cultivation For Human ImmunizationJ. Exp. Med.19376578780010.1084/jem.65.6.78719870634 9.GarskeT.van KerkhoveM.D.YactayoS.RonveauxO.LewisR.F.StaplesJ.E.PereaW.FergusonN.M.Yellow" exact="Fever" post="in Africa: Estimating the burden of disease and impact"/>
  <result pre="Med.19376578780010.1084/jem.65.6.78719870634 9.GarskeT.van KerkhoveM.D.YactayoS.RonveauxO.LewisR.F.StaplesJ.E.PereaW.FergusonN.M.Yellow Fever in Africa: Estimating the burden of" exact="disease" post="and impact of mass vaccination from outbreak and serological"/>
  <result pre="for Bigger DatasetsMol. Biol. Evol.2016331870187410.1093/molbev/msw05427004904 12.GrobbelaarA.A.WeyerJ.MoollaN.van Jansen VurenP.MoisesF.PaweskaJ.T.Resurgence of Yellow" exact="Fever" post="in Angola, 2015â€&quot;2016Emerg. Infect. Dis.2016221854185510.3201/eid2210.16081827536787 13.KraemerM.U.G.FariaN.R.ReinerR.C.GoldingN.NikolayB.StasseS.JohanssonM.A.SaljeH.FayeO.WintG.R.W.et al.Spread of yellow"/>
  <result pre="Yellow Fever in Angola, 2015â€&quot;2016Emerg. Infect. Dis.2016221854185510.3201/eid2210.16081827536787 13.KraemerM.U.G.FariaN.R.ReinerR.C.GoldingN.NikolayB.StasseS.JohanssonM.A.SaljeH.FayeO.WintG.R.W.et al.Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
  <result pre="feverScience201836184784810.1126/science.aau822530139914 16.FariaN.R.KraemerM.U.G.HillS.C.Goes de JesusJ.AguiarR.S.IaniF.C.M.XavierJ.QuickJ.Du PlessisL.DellicourS.et al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potentialScience201836189489910.1126/science.aat711530139911 17.DorigattiI.HamletA.AguasR.CattarinoL.CoriA.DonnellyC.A.GarskeT.ImaiN.FergusonN.M.International risk of yellow fever spread"/>
  <result pre="monitoring of yellow fever virus transmission potentialScience201836189489910.1126/science.aat711530139911 17.DorigattiI.HamletA.AguasR.CattarinoL.CoriA.DonnellyC.A.GarskeT.ImaiN.FergusonN.M.International risk of" exact="yellow fever" post="spread from the ongoing outbreak in Brazil, December 2016"/>
  <result pre="2017Euro Surveill.20172210.2807/1560-7917.ES.2017.22.28.30572 18.MonathT.P.Yellow fever: An updateLancet Infect. Dis.20011112010.1016/S1473-3099(01)00016-011871403 19.RiceC.M.GrakouiA.GallerR.ChambersT.J.Transcription of" exact="infectious" post="yellow fever RNA from full-length cDNA templates produced by"/>
  <result pre="Surveill.20172210.2807/1560-7917.ES.2017.22.28.30572 18.MonathT.P.Yellow fever: An updateLancet Infect. Dis.20011112010.1016/S1473-3099(01)00016-011871403 19.RiceC.M.GrakouiA.GallerR.ChambersT.J.Transcription of infectious" exact="yellow fever" post="RNA from full-length cDNA templates produced by in vitro"/>
  <result pre="vitro ligationNew Biol.198912852962487295 20.HahnC.S.DalrympleJ.M.StraussJ.H.RiceC.M.Comparison of the virulent Asibi strain of" exact="yellow fever" post="virus with the 17D vaccine strain derived from itProc."/>
  <result pre="vaccine strain derived from itProc. Natl. Acad. Sci. USA1987842019202310.1073/pnas.84.7.20193470774 21.BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.M.A" exact="stable" post="full-length yellow fever virus cDNA clone and the role"/>
  <result pre="derived from itProc. Natl. Acad. Sci. USA1987842019202310.1073/pnas.84.7.20193470774 21.BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.M.A stable full-length" exact="yellow fever" post="virus cDNA clone and the role of conserved RNA"/>
  <result pre="RNA elements in flavivirus replicationJ. Gen. Virol.2003841261126810.1099/vir.0.18860-012692292 22.RiceC.M.LenchesE.M.EddyS.R.ShinS.J.SheetsR.L.StraussJ.H.Nucleotide sequence of" exact="yellow fever" post="virus: Implications for flavivirus gene expression and evolutionScience198522972673310.1126/science.40237074023707 23.McElroyK.L.TsetsarkinK.A.VanlandinghamD.L.HiggsS.Characterization"/>
  <result pre="Implications for flavivirus gene expression and evolutionScience198522972673310.1126/science.40237074023707 23.McElroyK.L.TsetsarkinK.A.VanlandinghamD.L.HiggsS.Characterization of an" exact="infectious" post="clone of the wild-type yellow fever virus Asibi strain"/>
  <result pre="and evolutionScience198522972673310.1126/science.40237074023707 23.McElroyK.L.TsetsarkinK.A.VanlandinghamD.L.HiggsS.Characterization of an infectious clone of the wild-type" exact="yellow fever" post="virus Asibi strain that is able to infect and"/>
  <result pre="applications: A historical perspectiveAntivir. Res.2015114678510.1016/j.antiviral.2014.12.00725512228 25.FuruseY.Analysis of research intensity on" exact="infectious disease" post="by disease burden reveals which infectious diseases are neglected"/>
  <result pre="A historical perspectiveAntivir. Res.2015114678510.1016/j.antiviral.2014.12.00725512228 25.FuruseY.Analysis of research intensity on infectious" exact="disease" post="by disease burden reveals which infectious diseases are neglected"/>
  <result pre="perspectiveAntivir. Res.2015114678510.1016/j.antiviral.2014.12.00725512228 25.FuruseY.Analysis of research intensity on infectious disease by" exact="disease" post="burden reveals which infectious diseases are neglected by researchersProc."/>
  <result pre="research intensity on infectious disease by disease burden reveals which" exact="infectious diseases" post="are neglected by researchersProc. Natl. Acad. Sci. USA201911647848310.1073/pnas.181448411630598444 26.DouamF.PlossA.Yellow"/>
  <result pre="diseases are neglected by researchersProc. Natl. Acad. Sci. USA201911647848310.1073/pnas.181448411630598444 26.DouamF.PlossA.Yellow" exact="Fever" post="Virus: Knowledge Gaps Impeding the Fight Against an Old"/>
  <result pre="FoeTrends Microbiol.20182691392810.1016/j.tim.2018.05.01229933925 27.KlittingR.FischerC.DrexlerJ.F.GouldE.A.RoizD.PaupyC.de LamballerieX.What Does the Future Hold for Yellow" exact="Fever" post="Virus? (II)Genes2018942510.3390/genes9090425 28.collab: Centers for Disease Control and PreventionYellow"/>
  <result pre="Future Hold for Yellow Fever Virus? (II)Genes2018942510.3390/genes9090425 28.collab: Centers for" exact="Disease" post="Control and PreventionYellow Feverâ€&quot;Clinical and Laboratory Evaluation2015Available online: https://www.cdc.gov/yellowfever/healthcareproviders/healthcareproviders-clinlabeval.html(accessed"/>
  <result pre="12 August 2019) 29.QuaresmaJ.A.BarrosV.L.PagliariC.FernandesE.R.AndradeH.F.Jr.VasconcelosP.F.DuarteM.I.Hepatocyte lesions and cellular immune response in" exact="yellow fever" post="infectionTrans. R. Soc. Trop. Med. Hyg.200710116116810.1016/j.trstmh.2006.02.01916872652 30.BlakeL.E.Garcia-BlancoM.A.Human genetic variation"/>
  <result pre="infectionTrans. R. Soc. Trop. Med. Hyg.200710116116810.1016/j.trstmh.2006.02.01916872652 30.BlakeL.E.Garcia-BlancoM.A.Human genetic variation and" exact="yellow fever" post="mortality during 19th century U.S. epidemicsMBio20145e01253-1410.1128/mBio.01253-1424895309 31.TuboiS.H.CostaZ.G.da Costa VasconcelosP.F.HatchD.Clinical"/>
  <result pre="century U.S. epidemicsMBio20145e01253-1410.1128/mBio.01253-1424895309 31.TuboiS.H.CostaZ.G.da Costa VasconcelosP.F.HatchD.Clinical and epidemiological characteristics of" exact="yellow fever" post="in Brazil: Analysis of reported cases 1998-2002Trans. R. Soc."/>
  <result pre="32.OliveiraR.A.de Oliveira-FilhoE.F.FernandesI.V.A.BritoC.A.MarquesE.T.TenÃ³rioM.C.GilL.H.Previous dengue or Zika virus exposure can drive to" exact="infection" post="enhancement or neutralisation of other flavivirusesMem. Inst. Oswaldo Cruz2019114e19009810.1590/0074-0276019009831411310"/>
  <result pre="replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (Î²-D-2â€™-deoxy-2â€™-Î±-fluoro-2â€™-Î²-C-methyluridine) as an inhibitor of" exact="Dengue" post="virus replicationSci. Rep.20177634510.1038/s41598-017-06612-228740124 36.De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus"/>
  <result pre="targets the capsid proteinAntimicrob. Agents Chemother.201357152510.1128/AAC.01429-1223070172 40.PatkarC.G.LarsenM.OwstonM.SmithJ.L.KuhnR.J.Identification of inhibitors of" exact="yellow fever" post="virus replication using a replicon-based high-throughput assayAntimicrob. Agents Chemother.2009534103411410.1128/AAC.00074-0919651907"/>
  <result pre="assayAntimicrob. Agents Chemother.2009534103411410.1128/AAC.00074-0919651907 41.GuoF.WuS.JulanderJ.MaJ.ZhangX.KulpJ.CuconatiA.BlockT.M.DuY.GuoJ.-T.et al.A Novel Benzodiazepine Compound Inhibits Yellow" exact="Fever" post="Virus Infection by Specifically Targeting NS4B ProteinJ. Virol.201690107741078810.1128/JVI.01253-1627654301 42.PaccaC.C.SeverinoA.A.MondiniA.RahalP.Dâ€™Avila"/>
  <result pre="Chemother.2009534103411410.1128/AAC.00074-0919651907 41.GuoF.WuS.JulanderJ.MaJ.ZhangX.KulpJ.CuconatiA.BlockT.M.DuY.GuoJ.-T.et al.A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus" exact="Infection" post="by Specifically Targeting NS4B ProteinJ. Virol.201690107741078810.1128/JVI.01253-1627654301 42.PaccaC.C.SeverinoA.A.MondiniA.RahalP.Dâ€™Avila SG.CordeiroJ.A.NogueiraM.C.BronzoniR.V.NogueiraM.L.RNA interference"/>
  <result pre="by Specifically Targeting NS4B ProteinJ. Virol.201690107741078810.1128/JVI.01253-1627654301 42.PaccaC.C.SeverinoA.A.MondiniA.RahalP.Dâ€™Avila SG.CordeiroJ.A.NogueiraM.C.BronzoniR.V.NogueiraM.L.RNA interference inhibits" exact="yellow fever" post="virus replication in vitro and in vivoVirus Genes20093822423110.1007/s11262-009-0328-319169857 43.JulanderJ.G.Experimental"/>
  <result pre="46.PiersonT.C.KielianM.Flaviviruses: Braking the enteringCurr. Opin. Virol.2013331210.1016/j.coviro.2012.12.00123352692 47.PatkarC.G.JonesC.T.ChangY.-H.WarrierR.KuhnR.J.Functional requirements of the" exact="yellow fever" post="virus capsid proteinJ. Virol.2007816471648110.1128/JVI.02120-0617526891 48.Op de BeeckA.RouillÃ©Y.CaronM.DuvetS.DubuissonJ.The transmembrane domains"/>
  <result pre="BeeckA.RouillÃ©Y.CaronM.DuvetS.DubuissonJ.The transmembrane domains of the prM and E proteins of" exact="yellow fever" post="virus are endoplasmic reticulum localization signalsJ. Virol.200478125911260210.1128/JVI.78.22.12591-12602.200415507646 49.KielianM.Class II"/>
  <result pre="diversity in the flavivirus fusion peptideVirol. J.200852710.1186/1743-422X-5-2718275613 51.VolkD.E.MayF.J.GandhamS.H.A.AndersonA.von LindernJ.J.BeasleyD.W.C.BarrettA.D.T.GorensteinD.G.Structure of" exact="yellow fever" post="virus envelope protein domain IIIVirology2009394121810.1016/j.virol.2009.09.00119818466 52.RymanK.D.LedgerT.N.CampbellG.A.WatowichS.J.BarrettA.D.Mutation in a 17D-204"/>
  <result pre="17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of" exact="yellow fever" post="virus in miceVirology1998244596510.1006/viro.1998.90579581778 53.DaffisS.KontermannR.E.KorimbocusJ.ZellerH.KlenkH.-D.Ter MeulenJ.Antibody responses against wild-type yellow"/>
  <result pre="yellow fever virus in miceVirology1998244596510.1006/viro.1998.90579581778 53.DaffisS.KontermannR.E.KorimbocusJ.ZellerH.KlenkH.-D.Ter MeulenJ.Antibody responses against wild-type" exact="yellow fever" post="virus and the 17D vaccine strain: Characterization with human"/>
  <result pre="54.LuX.XiaoH.LiS.PangX.SongJ.LiuS.ChengH.LiY.WangX.HuangC.et al.Double Lock of a Human Neutralizing and Protective Monoclonal" exact="Antibody" post="Targeting the Yellow Fever Virus EnvelopeCell Rep.20192643844610.1016/j.celrep.2018.12.06530625326 55.PettersenE.F.GoddardT.D.HuangC.C.CouchG.S.GreenblattD.M.MengE.C.FerrinT.E.UCSF Chimera--a"/>
  <result pre="a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow" exact="Fever" post="Virus EnvelopeCell Rep.20192643844610.1016/j.celrep.2018.12.06530625326 55.PettersenE.F.GoddardT.D.HuangC.C.CouchG.S.GreenblattD.M.MengE.C.FerrinT.E.UCSF Chimera--a visualization system for exploratory"/>
  <result pre="for exploratory research and analysisJ. Comput. Chem.2004251605161210.1002/jcc.2008415264254 56.ChenZ.LiuL.LvY.ZhangW.LiJ.ZhangY.DiT.ZhangS.LiuJ.LiJ.et al.A fatal" exact="yellow fever" post="virus infection in China: Description and lessonsEmerg. Microbes Infect.20165e6910.1038/emi.2016.8927406389"/>
  <result pre="research and analysisJ. Comput. Chem.2004251605161210.1002/jcc.2008415264254 56.ChenZ.LiuL.LvY.ZhangW.LiJ.ZhangY.DiT.ZhangS.LiuJ.LiJ.et al.A fatal yellow fever" exact="virus infection" post="in China: Description and lessonsEmerg. Microbes Infect.20165e6910.1038/emi.2016.8927406389 57.HeinzF.X.AllisonS.L.Flavivirus structure"/>
  <result pre="and analysisJ. Comput. Chem.2004251605161210.1002/jcc.2008415264254 56.ChenZ.LiuL.LvY.ZhangW.LiJ.ZhangY.DiT.ZhangS.LiuJ.LiJ.et al.A fatal yellow fever virus" exact="infection" post="in China: Description and lessonsEmerg. Microbes Infect.20165e6910.1038/emi.2016.8927406389 57.HeinzF.X.AllisonS.L.Flavivirus structure"/>
  <result pre="60.ReschB.Product review on the monoclonal antibody palivizumab for prevention of" exact="respiratory" post="syncytial virus infectionHum. Vaccin. Immunother.2017132138214910.1080/21645515.2017.133761428605249 61.KumarR.QureshiH.DeshpandeS.BhattacharyaJ.Broadly neutralizing antibodies in"/>
  <result pre="of HIV infectionImmunol. Rev.201727531332310.1111/imr.1250628133794 63.MillerJ.L.de WetB.J.M.Martinez-PomaresL.RadcliffeC.M.DwekR.A.RuddP.M.GordonS.The mannose receptor mediates dengue" exact="virus infection" post="of macrophagesPLoS Pathog.20084e1710.1371/annotation/98b92fca-fa6e-4bf3-9b39-13b66b64047618266465 64.TassaneetrithepB.BurgessT.H.Granelli-PipernoA.TrumpfhellerC.FinkeJ.SunW.EllerM.A.PattanapanyasatK.SarasombathS.BirxD.L.et al.DC-SIGN (CD209) mediates dengue virus"/>
  <result pre="HIV infectionImmunol. Rev.201727531332310.1111/imr.1250628133794 63.MillerJ.L.de WetB.J.M.Martinez-PomaresL.RadcliffeC.M.DwekR.A.RuddP.M.GordonS.The mannose receptor mediates dengue virus" exact="infection" post="of macrophagesPLoS Pathog.20084e1710.1371/annotation/98b92fca-fa6e-4bf3-9b39-13b66b64047618266465 64.TassaneetrithepB.BurgessT.H.Granelli-PipernoA.TrumpfhellerC.FinkeJ.SunW.EllerM.A.PattanapanyasatK.SarasombathS.BirxD.L.et al.DC-SIGN (CD209) mediates dengue virus"/>
  <result pre="virus infection of macrophagesPLoS Pathog.20084e1710.1371/annotation/98b92fca-fa6e-4bf3-9b39-13b66b64047618266465 64.TassaneetrithepB.BurgessT.H.Granelli-PipernoA.TrumpfhellerC.FinkeJ.SunW.EllerM.A.PattanapanyasatK.SarasombathS.BirxD.L.et al.DC-SIGN (CD209) mediates dengue" exact="virus infection" post="of human dendritic cellsJ. Exp. Med.200319782382910.1084/jem.2002184012682107 65.KrishnanM.N.NgA.SukumaranB.GilfoyF.D.UchilP.D.SultanaH.BrassA.L.AdametzR.TsuiM.QianF.et al.RNA interference"/>
  <result pre="infection of macrophagesPLoS Pathog.20084e1710.1371/annotation/98b92fca-fa6e-4bf3-9b39-13b66b64047618266465 64.TassaneetrithepB.BurgessT.H.Granelli-PipernoA.TrumpfhellerC.FinkeJ.SunW.EllerM.A.PattanapanyasatK.SarasombathS.BirxD.L.et al.DC-SIGN (CD209) mediates dengue virus" exact="infection" post="of human dendritic cellsJ. Exp. Med.200319782382910.1084/jem.2002184012682107 65.KrishnanM.N.NgA.SukumaranB.GilfoyF.D.UchilP.D.SultanaH.BrassA.L.AdametzR.TsuiM.QianF.et al.RNA interference"/>
  <result pre="mediate dengue virus entryCell Host Microbe20121254455710.1016/j.chom.2012.08.00923084921 68.GermiR.CranceJ.-M.GarinD.GuimetJ.Lortat-JacobH.RuigrokR.W.H.ZarskiJ.-P.DrouetE.Heparan sulfate-mediated binding of" exact="infectious" post="dengue virus type 2 and yellow fever virusVirology200229216216810.1006/viro.2001.123211878919 69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role"/>
  <result pre="entryCell Host Microbe20121254455710.1016/j.chom.2012.08.00923084921 68.GermiR.CranceJ.-M.GarinD.GuimetJ.Lortat-JacobH.RuigrokR.W.H.ZarskiJ.-P.DrouetE.Heparan sulfate-mediated binding of infectious dengue virus" exact="type 2" post="and yellow fever virusVirology200229216216810.1006/viro.2001.123211878919 69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for"/>
  <result pre="68.GermiR.CranceJ.-M.GarinD.GuimetJ.Lortat-JacobH.RuigrokR.W.H.ZarskiJ.-P.DrouetE.Heparan sulfate-mediated binding of infectious dengue virus type 2 and" exact="yellow fever" post="virusVirology200229216216810.1006/viro.2001.123211878919 69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for attachment and entry"/>
  <result pre="virusVirology200229216216810.1006/viro.2001.123211878919 69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for attachment and entry of" exact="tick-borne encephalitis" post="virusVirology20033089210010.1016/S0042-6822(02)00097-112706093 70.ShuklaD.LiuJ.BlaiklockP.ShworakN.W.BaiX.EskoJ.D.CohenG.H.EisenbergR.J.RosenbergR.D.SpearP.G.A novel role for 3-O-sulfated heparan sulfate in"/>
  <result pre="69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for attachment and entry of tick-borne" exact="encephalitis" post="virusVirology20033089210010.1016/S0042-6822(02)00097-112706093 70.ShuklaD.LiuJ.BlaiklockP.ShworakN.W.BaiX.EskoJ.D.CohenG.H.EisenbergR.J.RosenbergR.D.SpearP.G.A novel role for 3-O-sulfated heparan sulfate in"/>
  <result pre="encephalitis virusVirology20033089210010.1016/S0042-6822(02)00097-112706093 70.ShuklaD.LiuJ.BlaiklockP.ShworakN.W.BaiX.EskoJ.D.CohenG.H.EisenbergR.J.RosenbergR.D.SpearP.G.A novel role for 3-O-sulfated heparan sulfate in" exact="herpes" post="simplex virus 1 entryCell199999132210.1016/S0092-8674(00)80058-610520990 71.PatelM.YanagishitaM.RoderiquezG.Bou-HabibD.C.OraveczT.HascallV.C.NorcrossM.A.Cell-surface heparan sulfate proteoglycan mediates"/>
  <result pre="simplex virus 1 entryCell199999132210.1016/S0092-8674(00)80058-610520990 71.PatelM.YanagishitaM.RoderiquezG.Bou-HabibD.C.OraveczT.HascallV.C.NorcrossM.A.Cell-surface heparan sulfate proteoglycan mediates HIV-1" exact="infection" post="of T-cell linesAIDS Res. Hum. Retrovir.1993916717410.1089/aid.1993.9.1678096145 72.LeeE.PavyM.YoungN.FreemanC.LobigsM.Antiviral effect of"/>
  <result pre="Res.200669313810.1016/j.antiviral.2005.08.00616309754 73.Perera-LecoinM.MeertensL.CarnecX.AmaraA.Flavivirus entry receptors: An updateViruses20136698810.3390/v601006924381034 74.Rodenhuis-ZybertI.A.WilschutJ.SmitJ.M.Dengue virus life cycle:" exact="Viral" post="and host factors modulating infectivityCell. Mol. Life Sci.2010672773278610.1007/s00018-010-0357-z20372965 75.SessionsO.M.BarrowsN.J.Souza-NetoJ.A.RobinsonT.J.HersheyC.L.RodgersM.A.RamirezJ.L.DimopoulosG.YangP.L.PearsonJ.L.et"/>
  <result pre="virus host factorsNature20094581047105010.1038/nature0796719396146 76.LiuK.QianY.JungY.-S.ZhouB.CaoR.ShenT.ShaoD.WeiJ.MaZ.ChenP.et al.mosGCTL-7, a C-Type Lectin Protein, Mediates" exact="Japanese Encephalitis" post="Virus Infection in MosquitoesJ. Virol.201791e01348-1610.1128/JVI.01348-16 77.ChengG.CoxJ.WangP.KrishnanM.N.DaiJ.QianF.AndersonJ.F.FikrigE.A C-type lectin collaborates"/>
  <result pre="host factorsNature20094581047105010.1038/nature0796719396146 76.LiuK.QianY.JungY.-S.ZhouB.CaoR.ShenT.ShaoD.WeiJ.MaZ.ChenP.et al.mosGCTL-7, a C-Type Lectin Protein, Mediates Japanese" exact="Encephalitis" post="Virus Infection in MosquitoesJ. Virol.201791e01348-1610.1128/JVI.01348-16 77.ChengG.CoxJ.WangP.KrishnanM.N.DaiJ.QianF.AndersonJ.F.FikrigE.A C-type lectin collaborates"/>
  <result pre="76.LiuK.QianY.JungY.-S.ZhouB.CaoR.ShenT.ShaoD.WeiJ.MaZ.ChenP.et al.mosGCTL-7, a C-Type Lectin Protein, Mediates Japanese Encephalitis Virus" exact="Infection" post="in MosquitoesJ. Virol.201791e01348-1610.1128/JVI.01348-16 77.ChengG.CoxJ.WangP.KrishnanM.N.DaiJ.QianF.AndersonJ.F.FikrigE.A C-type lectin collaborates with a"/>
  <result pre="collaborates with a CD45 phosphatase homolog to facilitate West Nile" exact="virus infection" post="of mosquitoesCell201014271472510.1016/j.cell.2010.07.03820797779 78.Fernandez-GarciaM.D.MeertensL.ChazalM.HafirassouM.L.DejarnacO.ZamborliniA.DespresP.SauvonnetN.Arenzana-SeisdedosF.JouvenetN.et al.Vaccine and Wild-Type Strains of Yellow"/>
  <result pre="with a CD45 phosphatase homolog to facilitate West Nile virus" exact="infection" post="of mosquitoesCell201014271472510.1016/j.cell.2010.07.03820797779 78.Fernandez-GarciaM.D.MeertensL.ChazalM.HafirassouM.L.DejarnacO.ZamborliniA.DespresP.SauvonnetN.Arenzana-SeisdedosF.JouvenetN.et al.Vaccine and Wild-Type Strains of Yellow"/>
  <result pre="infection of mosquitoesCell201014271472510.1016/j.cell.2010.07.03820797779 78.Fernandez-GarciaM.D.MeertensL.ChazalM.HafirassouM.L.DejarnacO.ZamborliniA.DespresP.SauvonnetN.Arenzana-SeisdedosF.JouvenetN.et al.Vaccine and Wild-Type Strains of Yellow" exact="Fever" post="Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral"/>
  <result pre="Immune ResponsesMBio2016710.1128/mBio.01956-15 79.PlowE.F.HaasT.A.ZhangL.LoftusJ.SmithJ.W.Ligand binding to integrinsJ. Biol. Chem.2000275217852178810.1074/jbc.R00000320010801897 80.ChambersT.J.NickellsM.Neuroadapted Yellow" exact="Fever" post="Virus 17D: Genetic and Biological Characterization of a Highly"/>
  <result pre="and Biological Characterization of a Highly Mouse-Neurovirulent Virus and Its" exact="Infectious" post="Molecular CloneJ. Virol.2001751091210.1128/JVI.75.22.10912-10922.200111602731 81.MaillyL.XiaoF.LupbergerJ.WilsonG.K.AubertP.DuongF.H.T.CalabreseD.LeboeufC.FofanaI.ThumannC.et al.Clearance of persistent hepatitis C"/>
  <result pre="and Its Infectious Molecular CloneJ. Virol.2001751091210.1128/JVI.75.22.10912-10922.200111602731 81.MaillyL.XiaoF.LupbergerJ.WilsonG.K.AubertP.DuongF.H.T.CalabreseD.LeboeufC.FofanaI.ThumannC.et al.Clearance of persistent" exact="hepatitis C" post="virus infection in humanized mice using a claudin-1-targeting monoclonal"/>
  <result pre="Infectious Molecular CloneJ. Virol.2001751091210.1128/JVI.75.22.10912-10922.200111602731 81.MaillyL.XiaoF.LupbergerJ.WilsonG.K.AubertP.DuongF.H.T.CalabreseD.LeboeufC.FofanaI.ThumannC.et al.Clearance of persistent hepatitis C" exact="virus infection" post="in humanized mice using a claudin-1-targeting monoclonal antibodyNat. Biotechnol.20153354955410.1038/nbt.317925798937"/>
  <result pre="Molecular CloneJ. Virol.2001751091210.1128/JVI.75.22.10912-10922.200111602731 81.MaillyL.XiaoF.LupbergerJ.WilsonG.K.AubertP.DuongF.H.T.CalabreseD.LeboeufC.FofanaI.ThumannC.et al.Clearance of persistent hepatitis C virus" exact="infection" post="in humanized mice using a claudin-1-targeting monoclonal antibodyNat. Biotechnol.20153354955410.1038/nbt.317925798937"/>
  <result pre="using a claudin-1-targeting monoclonal antibodyNat. Biotechnol.20153354955410.1038/nbt.317925798937 82.CamposR.K.WongB.XieX.LuY.-F.ShiP.-Y.PomponJ.Garcia-BlancoM.A.BradrickS.S.RPLP1 and RPLP2 Are" exact="Essential" post="Flavivirus Host Factors That Promote Early Viral Protein AccumulationJ."/>
  <result pre="and RPLP2 Are Essential Flavivirus Host Factors That Promote Early" exact="Viral" post="Protein AccumulationJ. Virol.20179110.1128/JVI.01706-1627974556 83.ChambersT.J.GrakouiA.RiceC.M.Processing of the yellow fever virus"/>
  <result pre="RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral" exact="Protein" post="AccumulationJ. Virol.20179110.1128/JVI.01706-1627974556 83.ChambersT.J.GrakouiA.RiceC.M.Processing of the yellow fever virus nonstructural"/>
  <result pre="That Promote Early Viral Protein AccumulationJ. Virol.20179110.1128/JVI.01706-1627974556 83.ChambersT.J.GrakouiA.RiceC.M.Processing of the" exact="yellow fever" post="virus nonstructural polyprotein: A catalytically active NS3 proteinase domain"/>
  <result pre="5â€² and 3â€² terminal regions in flavivirus RNA synthesis and" exact="viral" post="replicationVirology200837417018510.1016/j.virol.2007.12.03518234265 88.WenglerG.The NS3 nonstructural protein of flaviviruses contains an"/>
  <result pre="94.ChambersT.J.WeirR.C.GrakouiA.McCourtD.W.BazanJ.F.FletterickR.J.RiceC.M.Evidence that the N-terminal domain of nonstructural protein NS3 from" exact="yellow fever" post="virus is a serine protease responsible for site-specific cleavages"/>
  <result pre="is a serine protease responsible for site-specific cleavages in the" exact="viral" post="polyproteinProc. Natl. Acad. Sci. USA1990878898890210.1073/pnas.87.22.88982147282 95.WestawayE.G.MackenzieJ.M.KenneyM.T.JonesM.K.KhromykhA.A.Ultrastructure of Kunjin virus-infected"/>
  <result pre="protease-helicase as a target for antiviral drug developmentAntivir. Res.201511814815810.1016/j.antiviral.2015.03.01425842996 97.TanB.-H.FuJ.SugrueR.J.YapE.-H.ChanY.-C.TanY.H.Recombinant" exact="Dengue" post="Type 1 Virus NS5 Protein Expressed inEscherichia coliExhibits RNA-Dependent"/>
  <result pre="as a target for antiviral drug developmentAntivir. Res.201511814815810.1016/j.antiviral.2015.03.01425842996 97.TanB.-H.FuJ.SugrueR.J.YapE.-H.ChanY.-C.TanY.H.Recombinant Dengue" exact="Type 1" post="Virus NS5 Protein Expressed inEscherichia coliExhibits RNA-Dependent RNA Polymerase"/>
  <result pre="antiviral drug developmentAntivir. Res.201511814815810.1016/j.antiviral.2015.03.01425842996 97.TanB.-H.FuJ.SugrueR.J.YapE.-H.ChanY.-C.TanY.H.Recombinant Dengue Type 1 Virus NS5" exact="Protein" post="Expressed inEscherichia coliExhibits RNA-Dependent RNA Polymerase ActivityVirology199621631732510.1006/viro.1996.00678607261 98.KapoorM.ZhangL.RamachandraM.KusukawaJ.EbnerK.E.PadmanabhanR.Association between"/>
  <result pre="ActivityVirology199621631732510.1006/viro.1996.00678607261 98.KapoorM.ZhangL.RamachandraM.KusukawaJ.EbnerK.E.PadmanabhanR.Association between NS3 and NS5 proteins of dengue virus" exact="type 2" post="in the putative RNA replicase is linked to differential"/>
  <result pre="linked to differential phosphorylation of NS5J. Biol. Chem.1995270191001910610.1074/jbc.270.32.191007642575 99.BhattacharyaD.HooverS.FalkS.P.WeisblumB.VestlingM.StrikerR.Phosphorylation of" exact="yellow fever" post="virus NS5 alters methyltransferase activityVirology200838027628410.1016/j.virol.2008.07.01318757072 100.KÃ¼mmererB.M.RiceC.M.Mutations in the yellow"/>
  <result pre="yellow fever virus NS5 alters methyltransferase activityVirology200838027628410.1016/j.virol.2008.07.01318757072 100.KÃ¼mmererB.M.RiceC.M.Mutations in the" exact="yellow fever" post="virus nonstructural protein NS2A selectively block production of infectious"/>
  <result pre="yellow fever virus nonstructural protein NS2A selectively block production of" exact="infectious" post="particlesJ. Virol.2002764773478410.1128/JVI.76.10.4773-4784.200211967294 101.MillerS.KastnerS.Krijnse-LockerJ.BÃ¼hlerS.BartenschlagerR.The non-structural protein 4A of dengue virus"/>
  <result pre="by West Nile virus non-structural protein 4BPLoS ONE20149e8404010.1371/journal.pone.008404024465392 106.DesprÃ¨sP.GirardM.BouloyM.Characterization of" exact="yellow fever" post="virus proteins E and NS1 expressed in Vero and"/>
  <result pre="RNA chaperone activity of dengue virus core protein and other" exact="viral" post="RNA-interacting proteinsFEBS Lett.20115852575258110.1016/j.febslet.2011.06.03821771593 111.ElshuberS.AllisonS.L.HeinzF.X.MandlC.W.Cleavage of protein prM is necessary"/>
  <result pre="RNA-interacting proteinsFEBS Lett.20115852575258110.1016/j.febslet.2011.06.03821771593 111.ElshuberS.AllisonS.L.HeinzF.X.MandlC.W.Cleavage of protein prM is necessary for" exact="infection" post="of BHK-21 cells by tick-borne encephalitis virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715"/>
  <result pre="protein prM is necessary for infection of BHK-21 cells by" exact="tick-borne encephalitis" post="virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne encephalitis virus"/>
  <result pre="prM is necessary for infection of BHK-21 cells by tick-borne" exact="encephalitis" post="virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne encephalitis virus"/>
  <result pre="cells by tick-borne encephalitis virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of" exact="tick-borne encephalitis" post="virus by furinJ. Virol.199771847584819343204 113.QuaresmaJ.A.S.BarrosV.L.R.S.PagliariC.FernandesE.R.GuedesF.TakakuraC.F.H.AndradeH.F.VasconcelosP.F.C.DuarteM.I.S.Revisiting the liver in human"/>
  <result pre="by tick-borne encephalitis virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne" exact="encephalitis" post="virus by furinJ. Virol.199771847584819343204 113.QuaresmaJ.A.S.BarrosV.L.R.S.PagliariC.FernandesE.R.GuedesF.TakakuraC.F.H.AndradeH.F.VasconcelosP.F.C.DuarteM.I.S.Revisiting the liver in human"/>
  <result pre="patients with yellow feverJ. Infect. Dis.20041901821182710.1086/42501615499539 115.HackerU.T.JelinekT.ErhardtS.EiglerA.HartmannG.NothdurftH.D.EndresS.In Vivo synthesis of" exact="tumor" post="necrosis factor-alpha in healthy humans after live yellow fever"/>
  <result pre="synthesis of tumor necrosis factor-alpha in healthy humans after live" exact="yellow fever" post="vaccinationJ. Infect. Dis.1998377477810.1086/5178069498462 116.QuerecT.BennounaS.AlkanS.LaouarY.GordenK.FlavellR.AkiraS.AhmedR.PulendranB.Yellow fever vaccine YF-17D activates multiple"/>
  <result pre="stimulate polyvalent immunityJ. Exp. Med.200620341342410.1084/jem.2005172016461338 117.SinigagliaL.GraciasS.DÃ©cembreE.FritzM.BruniD.SmithN.HerbeuvalJ.-P.MartinA.DreuxM.TangyF.et al.Immature particles and capsid-free" exact="viral" post="RNA produced by Yellow fever virus-infected cells stimulate plasmacytoid"/>
  <result pre="Med.200620341342410.1084/jem.2005172016461338 117.SinigagliaL.GraciasS.DÃ©cembreE.FritzM.BruniD.SmithN.HerbeuvalJ.-P.MartinA.DreuxM.TangyF.et al.Immature particles and capsid-free viral RNA produced by" exact="Yellow fever" post="virus-infected cells stimulate plasmacytoid dendritic cells to secrete interferonsSci."/>
  <result pre="secrete interferonsSci. Rep.201881088910.1038/s41598-018-29235-730022130 118.Laurent-RolleM.MorrisonJ.RajsbaumR.MacleodJ.M.L.PisanelliG.PhamA.AyllonJ.MiorinL.MartinezC.tenOeverB.R.et al.The interferon signaling antagonist function of" exact="yellow fever" post="virus NS5 protein is activated by type I interferonCell"/>
  <result pre="function of yellow fever virus NS5 protein is activated by" exact="type I" post="interferonCell Host Microbe20141631432710.1016/j.chom.2014.07.01525211074 119.CongY.McArthurM.A.CohenM.JahrlingP.B.JanoskoK.B.JosleynN.KangK.ZhangT.HolbrookM.R.Characterization of Yellow Fever Virus Infection"/>
  <result pre="activated by type I interferonCell Host Microbe20141631432710.1016/j.chom.2014.07.01525211074 119.CongY.McArthurM.A.CohenM.JahrlingP.B.JanoskoK.B.JosleynN.KangK.ZhangT.HolbrookM.R.Characterization of Yellow" exact="Fever" post="Virus Infection of Human and Non-human Primate Antigen Presenting"/>
  <result pre="type I interferonCell Host Microbe20141631432710.1016/j.chom.2014.07.01525211074 119.CongY.McArthurM.A.CohenM.JahrlingP.B.JanoskoK.B.JosleynN.KangK.ZhangT.HolbrookM.R.Characterization of Yellow Fever Virus" exact="Infection" post="of Human and Non-human Primate Antigen Presenting Cells and"/>
  <result pre="exerts a critical early restriction on replication and dissemination of" exact="yellow fever" post="virus vaccine strain 17D-204NPJ Vaccines20183510.1038/s41541-017-0039-z29387474 122.DouamF.HrebikovaG.AlbrechtY.E.S.SellauJ.SharonY.DingQ.PlossA.Single-cell tracking of flavivirus"/>
  <result pre="flavivirus RNA uncovers species-specific interactions with the immune system dictating" exact="disease" post="outcomeNat. Commun.201781478110.1038/ncomms1478128290449 123.NevesP.C.C.SantosJ.R.TubarÃ£oL.N.BonaldoM.C.GallerR.Early IFN-gamma production after YF 17D vaccine"/>
  <result pre="immune responsesPLoS ONE20138e8195310.1371/journal.pone.008195324324734 124.MarquardtN.IvarssonM.A.BlomK.GonzalezV.D.BraunM.FalconerK.GustafssonR.Fogdell-HahnA.SandbergJ.K.MichaÃ«lssonJ.The Human NK Cell Response to Yellow" exact="Fever" post="Virus 17D Is Primarily Governed by NK Cell Differentiation"/>
  <result pre="in Resisting FlavivirusJ. Immunol. Res.20182018610658210.1155/2018/610658229888293 128.OlagnierD.ScholteF.E.M.ChiangC.AlbulescuI.C.NicholsC.HeZ.LinR.SnijderE.J.van HemertM.J.HiscottJ.Inhibition of dengue and" exact="chikungunya" post="virus infections by RIG-I-mediated type I interferon-independent stimulation of"/>
  <result pre="FlavivirusJ. Immunol. Res.20182018610658210.1155/2018/610658229888293 128.OlagnierD.ScholteF.E.M.ChiangC.AlbulescuI.C.NicholsC.HeZ.LinR.SnijderE.J.van HemertM.J.HiscottJ.Inhibition of dengue and chikungunya virus" exact="infections" post="by RIG-I-mediated type I interferon-independent stimulation of the innate"/>
  <result pre="128.OlagnierD.ScholteF.E.M.ChiangC.AlbulescuI.C.NicholsC.HeZ.LinR.SnijderE.J.van HemertM.J.HiscottJ.Inhibition of dengue and chikungunya virus infections by RIG-I-mediated" exact="type I" post="interferon-independent stimulation of the innate antiviral responseJ. Virol.2014884180419410.1128/JVI.03114-1324478443 129.FredericksenB.L.KellerB.C.FornekJ.KatzeM.G.GaleM.Establishment"/>
  <result pre="both RIG-I and MDA5 signaling through IPS-1J. Virol.20088260961610.1128/JVI.01305-0717977974 130.NazmiA.MukhopadhyayR.DuttaK.BasuA.STING mediates" exact="neuronal" post="innate immune response following Japanese encephalitis virus infectionSci. Rep.2012234710.1038/srep0034722470840"/>
  <result pre="through IPS-1J. Virol.20088260961610.1128/JVI.01305-0717977974 130.NazmiA.MukhopadhyayR.DuttaK.BasuA.STING mediates neuronal innate immune response following" exact="Japanese encephalitis" post="virus infectionSci. Rep.2012234710.1038/srep0034722470840 131.IshikawaH.BarberG.N.STING is an endoplasmic reticulum adaptor"/>
  <result pre="IPS-1J. Virol.20088260961610.1128/JVI.01305-0717977974 130.NazmiA.MukhopadhyayR.DuttaK.BasuA.STING mediates neuronal innate immune response following Japanese" exact="encephalitis" post="virus infectionSci. Rep.2012234710.1038/srep0034722470840 131.IshikawaH.BarberG.N.STING is an endoplasmic reticulum adaptor"/>
  <result pre="Immune Tolerance to N1-2â€™O-Methylated Self RNAImmunity201543415110.1016/j.immuni.2015.06.01526187414 133.CaiX.ChiuY.-H.ChenZ.J.The cGAS-cGAMP-STING pathway of" exact="cytosolic" post="DNA sensing and signalingMol. Cell20145428929610.1016/j.molcel.2014.03.04024766893 134.SchogginsJ.W.MacDuffD.A.ImanakaN.GaineyM.D.ShresthaB.EitsonJ.L.MarK.B.RichardsonR.B.RatushnyA.V.LitvakV.et al.Pan-viral specificity of"/>
  <result pre="new roles for cGAS in innate immunityNature201450569169510.1038/nature1286224284630 135.van GentM.GackM.U.Viral pathogenesis:" exact="Dengue" post="virus takes on cGASNat. Microbiol.201721705010.1038/nmicrobiol.2017.5028346454 136.AguirreS.LuthraP.Sanchez-AparicioM.T.MaestreA.M.PatelJ.LamotheF.FredericksA.C.TripathiS.ZhuT.Pintado-SilvaJ.et al.Dengue virus NS2B"/>
  <result pre="mitochondrial DNA sensing during infectionNat. Microbiol.201721703710.1038/nmicrobiol.2017.3728346446 137.IshikawaH.MaZ.BarberG.N.STING regulates intracellular DNA-mediated," exact="type I" post="interferon-dependent innate immunityNature200946178879210.1038/nature0847619776740 138.DingQ.GaskaJ.M.DouamF.WeiL.KimD.BalevM.HellerB.PlossA.Species-specific disruption of STING-dependent antiviral cellular"/>
  <result pre="proteaseProc. Natl. Acad. Sci. USA2018115E6310E631810.1073/pnas.180340611529915078 139.LamkanfiM.DixitV.M.Modulation of inflammasome pathways by" exact="bacterial" post="and viral pathogensJ. Immunol.201118759760210.4049/jimmunol.110022921734079 140.YiZ.SperzelL.NÃ¼rnbergerC.BredenbeekP.J.LubickK.J.BestS.M.StoyanovC.T.LawL.M.J.YuanZ.RiceC.M.et al.Identification and characterization of"/>
  <result pre="Acad. Sci. USA2018115E6310E631810.1073/pnas.180340611529915078 139.LamkanfiM.DixitV.M.Modulation of inflammasome pathways by bacterial and" exact="viral" post="pathogensJ. Immunol.201118759760210.4049/jimmunol.110022921734079 140.YiZ.SperzelL.NÃ¼rnbergerC.BredenbeekP.J.LubickK.J.BestS.M.StoyanovC.T.LawL.M.J.YuanZ.RiceC.M.et al.Identification and characterization of the host"/>
  <result pre="141.SchogginsJ.W.WilsonS.J.PanisM.MurphyM.Y.JonesC.T.BieniaszP.RiceC.M.A diverse range of gene products are effectors of the" exact="type I" post="interferon antiviral responseNature201147248148510.1038/nature0990721478870 142.RichardsonR.B.OhlsonM.B.EitsonJ.L.KumarA.McDougalM.B.BoysI.N.MarK.B.de La Cruz-RiveraP.C.DouglasC.KonopkaG.et al.A CRISPR screen"/>
  <result pre="reservoirs for flaviviruses (yellow fever, dengue 2 and St Louis" exact="encephalitis" post="viruses) in French GuianaTrans. R. Soc. Trop. Med. Hyg.20049840941210.1016/j.trstmh.2003.12.00315138077"/>
  <result pre="French GuianaTrans. R. Soc. Trop. Med. Hyg.20049840941210.1016/j.trstmh.2003.12.00315138077 144.JulanderJ.G.Animal models of" exact="yellow fever" post="and their application in clinical researchCurr. Opin. Virol.201618646910.1016/j.coviro.2016.03.01027093699 145.WilsonE.M.BialJ.TarlowB.BialG.JensenB.GreinerD.L.BrehmM.A.GrompeM.Extensive"/>
  <result pre="FRGN miceStem Cell Res.20141340441210.1016/j.scr.2014.08.00625310256 146.Strick-MarchandH.DusseauxM.DarcheS.HuntingtonN.D.LegrandN.Masse-RansonG.CorcuffE.AhodantinJ.WeijerK.SpitsH.et al.A novel mouse model for" exact="stable" post="engraftment of a human immune system and human hepatocytesPLoS"/>
  <result pre="human hepatocytesPLoS ONE201510e011982010.1371/journal.pone.011982025782010 147.BarrettA.D.GouldE.A.Comparison of neurovirulence of different strains of" exact="yellow fever" post="virus in miceJ. Gen. Virol.19866763163710.1099/0022-1317-67-4-6313958694 148.AlmeidaM.A.B.CardosoJ.d.C.Dos SantosE.da FonsecaD.F.CruzL.L.FaracoF.J.C.BerciniM.A.VettorelloK.C.PortoM.A.MohrdieckR.et al.Surveillance"/>
  <result pre="in miceJ. Gen. Virol.19866763163710.1099/0022-1317-67-4-6313958694 148.AlmeidaM.A.B.CardosoJ.d.C.Dos SantosE.da FonsecaD.F.CruzL.L.FaracoF.J.C.BerciniM.A.VettorelloK.C.PortoM.A.MohrdieckR.et al.Surveillance for yellow" exact="Fever" post="virus in non-human primates in southern Brazil, 2001â€&quot;2011: A"/>
  <result pre="Trop. Dis.20148e274110.1371/journal.pntd.000274124625681 149.LuethyL.N.EricksonA.K.JesudhasanP.R.IkizlerM.DermodyT.S.PfeifferJ.K.Comparison of three neurotropic viruses reveals differences in" exact="viral" post="dissemination to the central nervous systemVirology201648711010.1016/j.virol.2015.09.01926479325 150.FranzA.W.E.KantorA.M.PassarelliA.L.ClemR.J.Tissue Barriers to"/>
  <result pre="dissemination to the central nervous systemVirology201648711010.1016/j.virol.2015.09.01926479325 150.FranzA.W.E.KantorA.M.PassarelliA.L.ClemR.J.Tissue Barriers to Arbovirus" exact="Infection" post="in MosquitoesViruses201573741376710.3390/v707279526184281 151.DanetL.BeauclairG.BerthetM.MoratorioG.GraciasS.TangyF.ChoumetV.JouvenetN.Midgut barriers prevent the replication and dissemination"/>
  <result pre="MosquitoesViruses201573741376710.3390/v707279526184281 151.DanetL.BeauclairG.BerthetM.MoratorioG.GraciasS.TangyF.ChoumetV.JouvenetN.Midgut barriers prevent the replication and dissemination of the" exact="yellow fever" post="vaccine in Aedes aegyptiPLoS Negl. Trop. Dis.201957721310.1371/journal.pntd.0007299 152.EricksonA.K.PfeifferJ.K.Dynamic viral"/>
  <result pre="yellow fever vaccine in Aedes aegyptiPLoS Negl. Trop. Dis.201957721310.1371/journal.pntd.0007299 152.EricksonA.K.PfeifferJ.K.Dynamic" exact="viral" post="dissemination in mice infected with yellow fever virus strain"/>
  <result pre="Negl. Trop. Dis.201957721310.1371/journal.pntd.0007299 152.EricksonA.K.PfeifferJ.K.Dynamic viral dissemination in mice infected with" exact="yellow fever" post="virus strain 17DJ. Virol.201387123921239710.1128/JVI.02149-1324027319 153.DouamF.Soto AlbrechtY.E.HrebikovaG.SadiminE.DavidsonC.KotenkoS.V.PlossA.Type III Interferon-Mediated Signaling"/>
  <result pre="III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow" exact="Fever" post="Virus Infection In VivoMBio20178e00819-1710.1128/mBio.00819-1728811340 154.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying"/>
  <result pre="Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus" exact="Infection" post="In VivoMBio20178e00819-1710.1128/mBio.00819-1728811340 154.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying viscerotropic disease"/>
  <result pre="Virus Infection In VivoMBio20178e00819-1710.1128/mBio.00819-1728811340 154.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying viscerotropic" exact="disease" post="caused by yellow fever virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 155.MiorinL.Laurent-RolleM.PisanelliG.CoP.H.AlbrechtR.A.Garcia-SastreA.MorrisonJ.Host-Specific NS5"/>
  <result pre="VivoMBio20178e00819-1710.1128/mBio.00819-1728811340 154.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying viscerotropic disease caused by" exact="yellow fever" post="virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 155.MiorinL.Laurent-RolleM.PisanelliG.CoP.H.AlbrechtR.A.Garcia-SastreA.MorrisonJ.Host-Specific NS5 Ubiquitination Determines Yellow Fever"/>
  <result pre="yellow fever virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 155.MiorinL.Laurent-RolleM.PisanelliG.CoP.H.AlbrechtR.A.Garcia-SastreA.MorrisonJ.Host-Specific NS5 Ubiquitination Determines Yellow" exact="Fever" post="Virus TropismJ. Virol.20199310.1128/JVI.00151-1931043530 156.MinorP.The polio endgameHum. Vaccin. Immunother.2014102106210810.4161/21645515.2014.98111525608050 157.StokesA.BauerJ.H.HudsonN.P.The"/>
  <result pre="155.MiorinL.Laurent-RolleM.PisanelliG.CoP.H.AlbrechtR.A.Garcia-SastreA.MorrisonJ.Host-Specific NS5 Ubiquitination Determines Yellow Fever Virus TropismJ. Virol.20199310.1128/JVI.00151-1931043530 156.MinorP.The" exact="polio" post="endgameHum. Vaccin. Immunother.2014102106210810.4161/21645515.2014.98111525608050 157.StokesA.BauerJ.H.HudsonN.P.The transmission of yellow fever to"/>
  <result pre="TropismJ. Virol.20199310.1128/JVI.00151-1931043530 156.MinorP.The polio endgameHum. Vaccin. Immunother.2014102106210810.4161/21645515.2014.98111525608050 157.StokesA.BauerJ.H.HudsonN.P.The transmission of" exact="yellow fever" post="to Macacus rhesusRev. Med. Virol.20011114114810.1002/rmv.31111376477 158.RoukensA.H.VisserL.G.Yellow fever vaccine: Past,"/>
  <result pre="Opin. Biol. Ther.200881787179510.1517/14712598.8.11.178718847312 159.FerreiraC.C.Campi-AzevedoA.C.Peruhype-MagalhaesV.Costa-PereiraC.AlbuquerqueC.P.MunizL.F.Yokoy de SouzaT.OliveiraA.C.V.Martins-FilhoO.A.da MotaL.M.H.The 17D-204 and 17DD" exact="yellow fever" post="vaccines: An overview of major similarities and subtle differencesExpert"/>
  <result pre="2002MMWR Recomm. Rep.200251111 163.collab: Collaborative Group for Studies on Yellow" exact="Fever" post="VaccinesDuration of post-vaccination immunity against yellow fever in adultsVaccine2014324977498410.1016/j.vaccine.2014.07.02125090646"/>
  <result pre="for Studies on Yellow Fever VaccinesDuration of post-vaccination immunity against" exact="yellow fever" post="in adultsVaccine2014324977498410.1016/j.vaccine.2014.07.02125090646 164.GotuzzoE.YactayoS.CÃ³rdovaE.Efficacy and duration of immunity after yellow"/>
  <result pre="yellow fever in adultsVaccine2014324977498410.1016/j.vaccine.2014.07.02125090646 164.GotuzzoE.YactayoS.CÃ³rdovaE.Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: Systematic review on the need for a booster"/>
  <result pre="humoral and cellular parameters of immune activation after vaccination with" exact="yellow fever" post="virus strain 17D: A model of human flavivirus infectionJ."/>
  <result pre="Virol.19985615916710.1002/(SICI)1096-9071(199810)56:2&amp;lt;159::AID-JMV10&amp;gt;3.0.CO;2-B9746073 166.WietenR.W.JonkerE.F.F.van LeeuwenE.M.M.RemmerswaalE.B.M.ten BergeI.J.M.de VisserA.W.van GenderenP.J.J.GoorhuisA.VisserL.G.GrobuschM.P.et al.A Single 17D Yellow" exact="Fever" post="Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody"/>
  <result pre="Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing" exact="Antibody" post="and T-Cell Responses after VaccinationPLoS ONE201611e014987110.1371/journal.pone.014987126977808 167.NiedrigM.LademannM.EmmerichP.LafrenzM.Assessment of IgG"/>
  <result pre="Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and" exact="T-Cell" post="Responses after VaccinationPLoS ONE201611e014987110.1371/journal.pone.014987126977808 167.NiedrigM.LademannM.EmmerichP.LafrenzM.Assessment of IgG antibodies against"/>
  <result pre="T-Cell Responses after VaccinationPLoS ONE201611e014987110.1371/journal.pone.014987126977808 167.NiedrigM.LademannM.EmmerichP.LafrenzM.Assessment of IgG antibodies against" exact="yellow fever" post="virus after vaccination with 17D by different assays: Neutralization"/>
  <result pre="and ELISATrop. Med. Int. Health1999486787110.1046/j.1365-3156.1999.00496.x10632996 168.WatsonA.M.KlimstraW.B.T Cell-Mediated Immunity towards Yellow" exact="Fever" post="Virus and Useful Animal ModelsViruses201797710.3390/v9040077 169.QuerecT.D.PulendranB.Understanding the role of"/>
  <result pre="in the mechanism of action of the live attenuated Yellow" exact="Fever" post="Vaccine 17DAdv. Exp. Med. Biol.2007590435310.1007/978-0-387-34814-8_317191376 170.QuerecT.D.AkondyR.S.LeeE.K.CaoW.NakayaH.I.TeuwenD.PiraniA.GernertK.DengJ.MarzolfB.et al.Systems biology approach"/>
  <result pre="Med. Biol.2007590435310.1007/978-0-387-34814-8_317191376 170.QuerecT.D.AkondyR.S.LeeE.K.CaoW.NakayaH.I.TeuwenD.PiraniA.GernertK.DengJ.MarzolfB.et al.Systems biology approach predicts immunogenicity of the" exact="yellow fever" post="vaccine in humansNat. Immunol.20091011612510.1038/ni.168819029902 171.KasturiS.P.SkountzouI.AlbrechtR.A.KoutsonanosD.HuaT.NakayaH.I.RavindranR.StewartS.AlamM.KwissaM.et al.Programming the magnitude and"/>
  <result pre="172.Da Costa NevesP.C.MatosD.C.d.S.MarcovistzR.GallerR.TLR expression and NK cell activation after human" exact="yellow fever" post="vaccinationVaccine2009275543554910.1016/j.vaccine.2009.07.02819647065 173.GaucherD.TherrienR.KettafN.AngermannB.R.BoucherG.Filali-MouhimA.MoserJ.M.MehtaR.S.DrakeD.R.CastroE.et al.Yellow fever vaccine induces integrated multilineage and"/>
  <result pre="integrated multilineage and polyfunctional immune responsesJ. Exp. Med.20082053119313110.1084/jem.2008229219047440 174.MonathT.P.17D Yellow" exact="Fever" post="Virus VaccineAm. J. Trop. Med. Hyg.201389122510.4269/ajtmh.13-0443a24306031 175.TaoD.Barba-SpaethG.RaiU.NussenzweigV.RiceC.M.NussenzweigR.S.Yellow fever 17D"/>
  <result pre="vaccine vector for microbial CTL epitopes: Protection in a rodent" exact="malaria" post="modelJ. Exp. Med.200520120120910.1084/jem.2004152615657290 176.BredenbeekP.J.MolenkampR.SpaanW.J.DeubelV.MarianneauP.SalvatoM.S.MoshkoffD.ZapataJ.TikhonovI.PattersonJ.et al.A recombinant Yellow Fever 17D"/>
  <result pre="a rodent malaria modelJ. Exp. Med.200520120120910.1084/jem.2004152615657290 176.BredenbeekP.J.MolenkampR.SpaanW.J.DeubelV.MarianneauP.SalvatoM.S.MoshkoffD.ZapataJ.TikhonovI.PattersonJ.et al.A recombinant Yellow" exact="Fever" post="17D vaccine expressing Lassa virus glycoproteinsVirology200634529930410.1016/j.virol.2005.12.00116412488 177.FrancoD.LiW.QingF.StoyanovC.T.MoranT.RiceC.M.HoD.D.Evaluation of yellow"/>
  <result pre="Yellow Fever 17D vaccine expressing Lassa virus glycoproteinsVirology200634529930410.1016/j.virol.2005.12.00116412488 177.FrancoD.LiW.QingF.StoyanovC.T.MoranT.RiceC.M.HoD.D.Evaluation of" exact="yellow fever" post="virus 17D strain as a new vector for HIV-1"/>
  <result pre="of YFV 17D-based chimeric vaccines against dengue, West Nile and" exact="Japanese encephalitis" post="virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 179.StoyanovC.T.BoscardinS.B.DeroubaixS.Barba-SpaethG.FrancoD.NussenzweigR.S.NussenzweigM.RiceC.M.Immunogenicity and protective efficacy of a recombinant yellow"/>
  <result pre="YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese" exact="encephalitis" post="virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 179.StoyanovC.T.BoscardinS.B.DeroubaixS.Barba-SpaethG.FrancoD.NussenzweigR.S.NussenzweigM.RiceC.M.Immunogenicity and protective efficacy of a recombinant yellow"/>
  <result pre="Japanese encephalitis virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 179.StoyanovC.T.BoscardinS.B.DeroubaixS.Barba-SpaethG.FrancoD.NussenzweigR.S.NussenzweigM.RiceC.M.Immunogenicity and protective efficacy of a recombinant" exact="yellow fever" post="vaccine against the murine malarial parasite Plasmodium yoeliiVaccine2010284644465210.1016/j.vaccine.2010.04.07120451637 180.BonaldoM.C.SequeiraP.C.GallerR.The"/>
  <result pre="fever vaccine against the murine malarial parasite Plasmodium yoeliiVaccine2010284644465210.1016/j.vaccine.2010.04.07120451637 180.BonaldoM.C.SequeiraP.C.GallerR.The" exact="yellow fever" post="17D virus as a platform for new live attenuated"/>
  <result pre="attenuated vaccinesHum. Vaccin. Immunother.2014101256126510.4161/hv.2811724553128 181.BeckA.S.BarrettA.D.T.Current status and future prospects of" exact="yellow fever" post="vaccinesExpert Rev. Vaccines2015141479149210.1586/14760584.2015.108343026366673 182.OtshudiemaJ.O.NdakalaN.G.MawandaE.-T.K.TshapendaG.P.KimfutaJ.M.NsibuL.-R.N.GueyeA.S.DeeJ.PhilenR.M.GieseC.et al.Yellow Fever Outbreak - Kongo"/>
  <result pre="future prospects of yellow fever vaccinesExpert Rev. Vaccines2015141479149210.1586/14760584.2015.108343026366673 182.OtshudiemaJ.O.NdakalaN.G.MawandaE.-T.K.TshapendaG.P.KimfutaJ.M.NsibuL.-R.N.GueyeA.S.DeeJ.PhilenR.M.GieseC.et al.Yellow" exact="Fever" post="Outbreak - Kongo Central Province, Democratic Republic of the"/>
  <result pre="fever vaccinesExpert Rev. Vaccines2015141479149210.1586/14760584.2015.108343026366673 182.OtshudiemaJ.O.NdakalaN.G.MawandaE.-T.K.TshapendaG.P.KimfutaJ.M.NsibuL.-R.N.GueyeA.S.DeeJ.PhilenR.M.GieseC.et al.Yellow Fever Outbreak - Kongo" exact="Central" post="Province, Democratic Republic of the Congo, August 2016MMWR Morb."/>
  <result pre="the Congo, August 2016MMWR Morb. Mortal. Wkly. Rep.20176633533810.15585/mmwr.mm6612a528358796 183.VanniceK.Wilder-SmithA.HombachJ.Fractional-Dose Yellow" exact="Fever" post="Vaccinationâ€&quot;Advancing the Evidence BaseN. Engl. J. Med.201837960360510.1056/NEJMp180343329995585 184.BarrettA.D.T.Yellow Fever"/>
  <result pre="Yellow Fever Vaccinationâ€&quot;Advancing the Evidence BaseN. Engl. J. Med.201837960360510.1056/NEJMp180343329995585 184.BarrettA.D.T.Yellow" exact="Fever" post="in Angola and Beyond--The Problem of Vaccine Supply and"/>
  <result pre="Dis.20172112312410.1016/j.bjid.2017.02.00428336123 186.PossasC.Lourenco-de-OliveiraR.TauilP.L.PinheiroF.P.PissinattiA.CunhaR.V.D.FreireM.MartinsR.M.HommaA.Yellow fever outbreak in Brazil: The puzzle of rapid" exact="viral" post="spread and challenges for immunisationMem. Inst. Oswaldo Cruz2018113e18027810.1590/0074-0276018027830427974 187.JonkerE.F.VisserL.G.RoukensA.H.Advances"/>
  <result pre="challenges for immunisationMem. Inst. Oswaldo Cruz2018113e18027810.1590/0074-0276018027830427974 187.JonkerE.F.VisserL.G.RoukensA.H.Advances and controversies in" exact="yellow fever" post="vaccinationTher. Adv. Vaccines2013114415210.1177/205101361349895424757521 188.KartogluU.MilstienJ.Tools and approaches to ensure quality"/>
  <result pre="antipolioviral activityJ. Virol.2014884403441310.1128/JVI.03402-1324501405 191.ChanK.R.GanE.S.ChanC.Y.Y.LiangC.LowJ.Z.H.ZhangS.L.-X.OngE.Z.BhattaA.WijayaL.LeeY.H.et al.Metabolic perturbations and cellular stress underpin" exact="susceptibility to" post="symptomatic live-attenuated yellow fever infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease"/>
  <result pre="Virol.2014884403441310.1128/JVI.03402-1324501405 191.ChanK.R.GanE.S.ChanC.Y.Y.LiangC.LowJ.Z.H.ZhangS.L.-X.OngE.Z.BhattaA.WijayaL.LeeY.H.et al.Metabolic perturbations and cellular stress underpin susceptibility to" exact="symptomatic" post="live-attenuated yellow fever infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease associated"/>
  <result pre="al.Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated" exact="yellow fever" post="infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease associated with 17D-204 yellow"/>
  <result pre="susceptibility to symptomatic live-attenuated yellow fever infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic" exact="disease" post="associated with 17D-204 yellow fever vaccination: A report of"/>
  <result pre="yellow fever infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease associated with 17D-204" exact="yellow fever" post="vaccination: A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 193.ThomasR.E.LorenzettiD.L.SpraginsW.JacksonD.WilliamsonT.Active and passive"/>
  <result pre="A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 193.ThomasR.E.LorenzettiD.L.SpraginsW.JacksonD.WilliamsonT.Active and passive surveillance of" exact="yellow fever" post="vaccine 17D or 17DD-associated serious adverse events: Systematic reviewVaccine2011294544455510.1016/j.vaccine.2011.04.05521549787"/>
  <result pre="reviewRev. Panam Salud Publica201842e7510.26633/RPSP.2018.7531093103 195.BelsherJ.L.GayP.BrintonM.DellaVallaJ.RidenourR.LanciottiR.PerelyginA.ZakiS.PaddockC.QuerecT.et al.Fatal multiorgan failure due to" exact="yellow fever" post="vaccine-associated viscerotropic diseaseVaccine2007258480848510.1016/j.vaccine.2007.08.06118023511 196.Conesa-BotellaA.ColebundersR.Response to â€œCase of yellow fever"/>
  <result pre="to yellow fever vaccine-associated viscerotropic diseaseVaccine2007258480848510.1016/j.vaccine.2007.08.06118023511 196.Conesa-BotellaA.ColebundersR.Response to â€œCase of" exact="yellow fever" post="vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune"/>
  <result pre="viscerotropic diseaseVaccine2007258480848510.1016/j.vaccine.2007.08.06118023511 196.Conesa-BotellaA.ColebundersR.Response to â€œCase of yellow fever vaccine-associated viscerotropic" exact="disease" post="with prolonged viremia, robust adaptive immune responses, and polymorphisms"/>
  <result pre="CCR5 and RANTES genesJ. Infect. Dis.200919960110.1086/59620919281308 197.HernandezN.BucciolG.MoensL.Le PenJ.ShahrooeiM.GoudourisE.ShirkaniA.Changi-AshtianiM.Rokni-ZadehH.SayarE.H.et al.Inherited IFNAR1" exact="deficiency" post="in otherwise healthy patients with adverse reaction to measles"/>
  <result pre="IFNAR1 deficiency in otherwise healthy patients with adverse reaction to" exact="measles" post="and yellow fever live vaccinesJ. Exp. Med.201910.1084/jem.20182295 198.CalisherC.H.WoodallJ.P.Yellow Fever-More"/>
  <result pre="in otherwise healthy patients with adverse reaction to measles and" exact="yellow fever" post="live vaccinesJ. Exp. Med.201910.1084/jem.20182295 198.CalisherC.H.WoodallJ.P.Yellow Fever-More a Policy and"/>
  <result pre="Dis.2016221859186010.3201/eid2210.16087527479749 199.collab: World Health OrganizationA Global Strategy to Eliminate Yellow" exact="Fever" post="Epidemics 2017â€&quot;2026World Health OrganizationGeneva, Switzerland2018 200.JeanK.DonnellyC.A.FergusonN.M.GarskeT.A Meta-Analysis of Serological"/>
  <result pre="OrganizationGeneva, Switzerland2018 200.JeanK.DonnellyC.A.FergusonN.M.GarskeT.A Meta-Analysis of Serological Response Associated with Yellow" exact="Fever" post="VaccinationAm. J. Trop. Med. Hyg.2016951435143910.4269/ajtmh.16-040127928091 201.ZhaoS.StoneL.GaoD.HeD.Modelling the large-scale yellow"/>
  <result pre="Yellow Fever VaccinationAm. J. Trop. Med. Hyg.2016951435143910.4269/ajtmh.16-040127928091 201.ZhaoS.StoneL.GaoD.HeD.Modelling the large-scale" exact="yellow fever" post="outbreak in Luanda, Angola, and the impact of vaccinationPLoS"/>
  <result pre="Trop. Dis.201812e000615810.1371/journal.pntd.000615829338001 202.HamletA.JeanK.YactayoS.BenzlerJ.CibrelusL.FergusonN.GarskeT.POLICI: A web application for visualising and extracting" exact="yellow fever" post="vaccination coverage in AfricaVaccine2019371384138810.1016/j.vaccine.2019.01.07430770224 203.SchaferB.HolzerG.W.JoachimsthalerA.CoulibalyS.SchwendingerM.CroweB.A.KreilT.R.BarrettP.N.FalknerF.G.Pre-clinical efficacy and safety of"/>
  <result pre="203.SchaferB.HolzerG.W.JoachimsthalerA.CoulibalyS.SchwendingerM.CroweB.A.KreilT.R.BarrettP.N.FalknerF.G.Pre-clinical efficacy and safety of experimental vaccines based on non-replicating" exact="vaccinia" post="vectors against yellow feverPLoS ONE20116e2450510.1371/journal.pone.002450521931732 204.MacielM.Jr.Cruz FdaS.CordeiroM.T.da MottaM.A.CassemiroK.M.Maia RdeC.de"/>
  <result pre="204.MacielM.Jr.Cruz FdaS.CordeiroM.T.da MottaM.A.CassemiroK.M.Maia RdeC.de FigueiredoR.C.GallerR.Freire MdaS.AugustJ.T.et al.A DNA vaccine against" exact="yellow fever" post="virus: Development and evaluationPLoS Negl. Trop. Dis.20159e000369310.1371/journal.pntd.000369325875109 205.TotteyS.ShojiY.JonesR.M.ChichesterJ.A.GreenB.J.MusiychukK.SiH.MancevaS.D.RheeA.ShamloulM.et al.Plant-Produced"/>
  <result pre="Negl. Trop. Dis.20159e000369310.1371/journal.pntd.000369325875109 205.TotteyS.ShojiY.JonesR.M.ChichesterJ.A.GreenB.J.MusiychukK.SiH.MancevaS.D.RheeA.ShamloulM.et al.Plant-Produced Subunit Vaccine Candidates against Yellow" exact="Fever" post="Induce Virus Neutralizing Antibodies and Confer Protection against Viral"/>
  <result pre="Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against" exact="Viral" post="Challenge in Animal ModelsAm. J. Trop. Med. Hyg.20189842043110.4269/ajtmh.16-029329231157 206.TripathiN.K.ShrivastavaA.Recent"/>
  <result pre="ModelsAm. J. Trop. Med. Hyg.20189842043110.4269/ajtmh.16-029329231157 206.TripathiN.K.ShrivastavaA.Recent Developments in Recombinant Protein-Based" exact="Dengue" post="VaccinesFront. Immunol.20189191910.3389/fimmu.2018.0191930190720 207.KheraT.BehrendtP.BankwitzD.BrownR.J.P.TodtD.DoepkeM.KhanA.G.SchulzeK.LawJ.LoganM.et al.Functional and immunogenic characterization of diverse"/>
  <result pre="Protection Conferred by the VSV-Vectored Ebola Virus VaccineMBio20191010.1128/mBio.01597-19 209.MonathT.P.LeeC.K.JulanderJ.G.BrownA.BeasleyD.W.WattsD.M.HaymanE.GuertinP.MakowieckiJ.CrowellJ.et al.Inactivated" exact="yellow fever" post="17D vaccine: Development and nonclinical safety, immunogenicity and protective"/>
  <result pre="vaccination: Past, present and futureFuture Microbiol.20151079180810.2217/fmb.15.1925824845 215.KlittingR.RizikiT.MoureauG.PiorkowskiG.GouldE.A.de LamballerieX.Exploratory re-encoding of" exact="yellow fever" post="virus genome: New insights for the design of live-attenuated"/>
  <result pre="Evol.20184vey02110.1093/ve/vey02130057792 216.MartinezM.A.Jordan-PaizA.FrancoS.NevotM.Synonymous Virus Genome Recoding as a Tool to Impact" exact="Viral" post="FitnessTrends Microbiol.20162413414710.1016/j.tim.2015.11.00226646373 217.NougairedeA.de FabritusL.AubryF.GouldE.A.HolmesE.C.de LamballerieX.Random codon re-encoding induces stable"/>
  <result pre="Impact Viral FitnessTrends Microbiol.20162413414710.1016/j.tim.2015.11.00226646373 217.NougairedeA.de FabritusL.AubryF.GouldE.A.HolmesE.C.de LamballerieX.Random codon re-encoding induces" exact="stable" post="reduction of replicative fitness of Chikungunya virus in primate"/>
  <result pre="in primate and mosquito cellsPLoS Pathog.20139e100317210.1371/journal.ppat.100317223436995 218.de FabritusL.NougairedeA.AubryF.GouldE.A.de LamballerieX.Attenuation of" exact="tick-borne encephalitis" post="virus using large-scale random codon re-encodingPLoS Pathog.201511e100473810.1371/journal.ppat.100473825734338 219.CarringtonC.V.F.AugusteA.J.Evolutionary and"/>
  <result pre="primate and mosquito cellsPLoS Pathog.20139e100317210.1371/journal.ppat.100317223436995 218.de FabritusL.NougairedeA.AubryF.GouldE.A.de LamballerieX.Attenuation of tick-borne" exact="encephalitis" post="virus using large-scale random codon re-encodingPLoS Pathog.201511e100473810.1371/journal.ppat.100473825734338 219.CarringtonC.V.F.AugusteA.J.Evolutionary and"/>
  <result pre="219.CarringtonC.V.F.AugusteA.J.Evolutionary and ecological factors underlying the tempo and distribution of" exact="yellow fever" post="virus activityInfect. Genet. Evol.20131319821010.1016/j.meegid.2012.08.01522981999 220.LemoineF.CorreiaD.LefortV.Doppelt-AzeroualO.MareuilF.Cohen-BoulakiaS.GascuelO.NGPhylogeny.fr: New generation phylogenetic services"/>
  <result pre="frontier of genome engineering with CRISPR-Cas9Science2014346125809610.1126/science.125809625430774 223.PugachevK.V.GuirakhooF.OcranS.W.MitchellF.ParsonsM.PenalC.GirakhooS.PougatchevaS.O.ArroyoJ.TrentD.W.et al.High fidelity of" exact="yellow fever" post="virus RNA polymeraseJ. Virol.2004781032103810.1128/JVI.78.2.1032-1038.200414694136 224.VlachakisD.KoumandouV.L.KossidaS.A holistic evolutionary and structural"/>
  <result pre="of a multiplexed amplification and next generation sequencing method for" exact="viral" post="hemorrhagic fever diagnosticsPLoS Negl. Trop. Dis.201711e000607510.1371/journal.pntd.000607529155823 227.McMullanL.K.FraceM.SammonsS.A.ShoemakerT.BalinandiS.WamalaJ.F.LutwamaJ.J.DowningR.G.StroeherU.MacNeilA.et al.Using next"/>
  <result pre="Negl. Trop. Dis.201711e000607510.1371/journal.pntd.000607529155823 227.McMullanL.K.FraceM.SammonsS.A.ShoemakerT.BalinandiS.WamalaJ.F.LutwamaJ.J.DowningR.G.StroeherU.MacNeilA.et al.Using next generation sequencing to identify" exact="yellow fever" post="virus in UgandaVirology20124221510.1016/j.virol.2011.08.02421962764 228.QuickJ.LomanN.J.DuraffourS.SimpsonJ.T.SeveriE.CowleyL.BoreJ.A.KoundounoR.DudasG.MikhailA.et al.Real-time, portable genome sequencing for"/>
  <result pre="229.KafetzopoulouL.E.PullanS.T.LemeyP.SuchardM.A.EhichioyaD.U.PahlmannM.ThielebeinA.HinzmannJ.OestereichL.WozniakD.M.et al.Metagenomic sequencing at the epicenter of the Nigeria 2018" exact="Lassa fever" post="outbreakScience2019363747710.1126/science.aau934330606844 230.JainM.OlsenH.E.PatenB.AkesonM.The Oxford Nanopore MinION: Delivery of nanopore sequencing"/>
  <result pre="epidemicInt. J. Infect. Dis.2016489810310.1016/j.ijid.2016.04.02527156836 233.ChenC.JiangD.NiM.LiJ.ChenZ.LiuJ.YeH.WongG.LiW.ZhangY.et al.Phylogenomic analysis unravels evolution of" exact="yellow fever" post="virus within hostsPLoS Negl. Trop. Dis.201812e000673810.1371/journal.pntd.000673830188905 234.SallA.A.FayeO.DialloM.FirthC.KitchenA.HolmesE.C.Yellow fever virus"/>
  <result pre="Arbovirus Vertical Transmission in MosquitoesPLoS Pathog.201612e100554810.1371/journal.ppat.100554827171170 237.DialloM.ThonnonJ.FontenilleD.Vertical transmission of the" exact="yellow fever" post="virus by Aedes aegypti (Diptera, Culicidae): Dynamics of infection"/>
  <result pre="yellow fever virus by Aedes aegypti (Diptera, Culicidae): Dynamics of" exact="infection" post="in F1 adult progeny of orally infected femalesAm. J."/>
  <result pre="by Aedes aegypti (Diptera, Culicidae): Dynamics of infection in F1" exact="adult" post="progeny of orally infected femalesAm. J. Trop. Med. Hyg.20006215115610.4269/ajtmh.2000.62.15110761742"/>
  <result pre="Trop. Med. Hyg.20006215115610.4269/ajtmh.2000.62.15110761742 238.AmraouiF.VazeilleM.FaillouxA.B.French Aedes albopictus are able to transmit" exact="yellow fever" post="virusEuro Surveill.20162110.2807/1560-7917.ES.2016.21.39.30361 239.KraemerM.U.G.ReinerR.C.Jr.BradyO.J.MessinaJ.P.GilbertM.PigottD.M.YiD.JohnsonK.EarlL.MarczakL.B.et al.Past and future spread of the"/>
  <result pre="albopictusNat. Microbiol.2019485486310.1038/s41564-019-0376-y30833735 240.HamrickP.N.AldighieriS.MachadoG.LeonelD.G.VilcaL.M.UrionaS.SchneiderM.C.Geographic patterns and environmental factors associated with human" exact="yellow fever" post="presence in the AmericasPLoS Negl. Trop. Dis.201711e000589710.1371/journal.pntd.000589728886023 241.KupferschmidtK.After 40"/>
  <result pre="generated using MEGA7 [11] from a conserved region of the" exact="viral" post="RNA dependant RNA polymerase (RdRp: NS5 or NS5B) and"/>
  <result pre="NS2B, NS3, NS4A, NS4B, and NS5). The genome has methylated" exact="type 1" post="cap at the 5â€² end and is not polyadenylated."/>
  <result pre="1 cap at the 5â€² end and is not polyadenylated." exact="Secondary" post="structures (stem-loop A and B; SLA/SLB) in the 5â€²"/>
  <result pre="translation and RNA synthesis. The polyprotein is post-translationally modified by" exact="viral" post="and host proteases into 10 mature proteins which are"/>
  <result pre="the YFV phylogeny contain closely related isolates from the 2016â€&quot;2017" exact="Brazilian" post="outbreak (n = 52, green triangle), the 2015â€&quot;2016 Angolan"/>
  <result pre="represent YFV sequences isolated from non-human primates during the 2016â€&quot;2017" exact="Brazilian" post="epidemic, which co-cluster with previously sampled non-outbreak sequences and"/>
 </snippets>
</snippetsTree>
